Changes to the development pipeline Q3 2020 update

New to phase I New to phase II New to phase III New to registration 7 NMEs: 2 NMEs: 4 NMEs: 1 NME: RG6091 UBE3A LNA - Angelman syndrome RG7992 FGFR1 x KLB - NASH RG6107 crovalimab - PNH RG6396 Gavreto (pralsetinib) - RET fusion- RG6286 NME - colorectal cancer CHU Oncolytic Type 5 adenovirus - esophageal RG6413+RG6412 REGN-COV2 - SARS-CoV-2 positive NSCLC RG6315 NME - systemic sclerosis cancer prophylaxis RG6330 KRAS G12C - KRAS-mutant solid tumors RG6171 SERD(3) ER+/HER2 - metastatic breast 2 AIs: RG6418 NLRP3 inhibitor - inflammation 5 AIs: cancer RG3648 Xolair - asthma home use 4D-MT 4D-R125 - X-linked retinitis pigmentosa RG6171 SERD(3) - neoadjuvant HR+ breast 7 AIs: RG6396 Gavreto (pralsetinitb) - RET-mutant CHU CD137 agonist switch antibody - solid tumors cancer RG6058 tiragolumab+Tecentriq - stage III medullary thyroid cancer (MTC) RG6413+RG6412 REGN-COV2 - COVID-19+ unresectable 1L NSCLC 2 AIs: adult – ambulatory RG6058 tiragolumab+Tecentriq - locally adv RG7440 ipatasertib+Tecentriq - prostate cancer RG6413+RG6412 REGN-COV2 - COVID-19+ esophageal cancer previously treated with androgen receptor-targeted adult – hospitalized RG6321 PDS with ranibizumab - diabetic therapy retinopathy RG7446 Tecentriq+Venclexta - maintenance 1L RG7159 Gazyva - lupus nephritis ES-SCLC RG7601 Venclexta - 1L MDS RG7446 Tecentriq+cabozantinib - adv RCC RG7446 Tecentriq+cabozantinib - 2L NSCLC Removed from phase I Removed from phase II Removed from phase III Approvals

2 NMEs: 2 AIs: 3 AIs: 3 NMEs approved in US RG6000 DLK inhibitor - ALS RG7421 Cotellic+Tecentriq+/- taxane - TNBC RG7413 etrolizumab - ulceritis colitis RG7916 Evrysdi - SMA RG7861 anti-S.aureus - infectious diseases RG7596 Polivy - r/r FL* RG7446 Tecentriq+paclitaxel - 1L TNBC RG6168 Enspryng - NMOSD RG7446 Tecentriq+ chemo + Avastin - ovarian RG6396 Gavreto - RET fusion positive NSCLC cancer 1 NME approved in EU RG6268 Rozlytrek - ROS1+ NSCLC 1 AI approved in US RG7421 Cotellic+Zelboraf+Tecentriq - 1L+ BRAFm melanoma 1 AI approved in EU RG6268 Rozlytrek - NTRK+ tumor-agnostic Status as of October 15, 2020 * FL cohort removed, DLBCL continues 1 Roche Group development pipeline

Phase I (45 NMEs + 17 AIs) Phase II (21 NMEs + 14 AIs)

RG6026 glofitamab combos heme tumors RG7769 PD1 x TIM3 solid tumors RG6171 SERD (3) neoadjuvant HR+ BC RG6058 tiragolumab combos heme & solid tumors RG7802 cibisatamab ± T solid tumors RG6180 iNeST* + pembrolizumab malignant melanoma RG6076 CD19-4-1BBL heme tumors RG7827 FAP-4-1BBL + T solid tumors RG6357 SPK-8011 hemophilia A RG6115 TLR7 agonist (4) HCC RG7828 mosunetuzumab combos heme tumors RG6358 SPK-8016 hemophilia A with inhibitors to factor VIII RG6139 PD1 x LAG3 solid tumors RG7876 selicrelumab combos solid tumors tiragolumab + T NSCLC RG6058 RG6160 FcRH5 x CD3 r/r MM CHU FIXa x FX hemophilia tiragolumab + T cervical cancer RG6171 SERD (3) ER+/HER2- mBC 1L CHU glypican-3 x CD3 solid tumors RG7446 Tecentriq SC NSCLC RG6180 iNeST*± T solid tumors CHU codrituzumab HCC Venclexta + fulvestrant 2L HR+BC RG7601 RG6185 belvarafenib (pan-RAF inh)+Cotellic solid tumors CHU CD137 switch antibody solid tumors Venclexta + carfilzomib r/r MM t(11:14) RG6194 HER2 x CD3 BC CHU - .. solid tumors & endometriosis CHU Oncolytic Type 5 adenovirus esophageal cancer RG6279 PD1-IL2v solid tumors SQZ PBMC vaccine solid tumors RG6149 ST2 MAb asthma RG6286 NME colorectal cancer RG6151 - asthma RG6173 anti-tryptase asthma RG6290 MAGE-A4 ImmTAC solid tumors RG6244 - asthma rhPTX-2 (PRM-151) myelofibrosis RG6354 RG6292 CD25 MAb solid tumors RG6287 - IBD rhPTX-2 (PRM-151) . idiopathic pulmonary fibrosis RG6296 BCMA x CD16a r/r MM RG6418 NLRP3 inh inflammation RG7845 fenebrutinib RA RG6323 IL15/IL15Ra-Fc solid tumors RG6315 NME systemic sclerosis RG7880 IL22-Fc inflammatory diseases RG6330 KRAS G12C solid tumors RG7835 IgG–IL2 autoimmune diseases RG6149/RG7880 ST2 MAb or IL22-Fc COVID-19 pneumonia ipatasertib + Taxane + T TNBC RG6084 - HBV NOV TLR4 MAb autoimmune diseases RG7440 ipatasertib + rucaparib mCRPC, solid tumors RG6346 HBV siRNA HBV RG7854+RG7907 TLR7 ago(3) + CpAM (2) HBV ipatasertib .prostate cancer, pretreated RG6091 UBE3A LNA Angelman syndrome RG6413+ REGN-COV2 nAbs . . COVID-19+ adult-ambulatory Morpheus platform solid tumors RG6102 brain shuttle gantenerumab Alzheimer’s RG6412 REGN-COV2 nAbs COVID-19+ adult-hospitalised T + Avastin + Cotellic 2/3L CRC RG6237 - neuromuscular disorders RG7992 FGFR1 x KLB MAb NASH T ± Avastin ± chemo HCC, GC, PaC RG7637 - . neurodevelopmental disorders IONIS ASO factor B IgA nephropathy T + anti-CD20 combos heme tumors RG7816 GABA Aa5 PAM autism RG6100 semorinemab Alzheimer’s RG7446 T + K/HP HER2+ BC RG6179 - DME RG6356 microdystrophin (SRP-9001) DMD T + rucaparib ovarian cancer RG6247 4D-R110 choroideremia RG7412 crenezumab familial Alzheimer’s healthy pts T + CD47 MAb r/r AML RG7921 - nAMD RG7906 ralmitaront schizophrenia T + Venclexta maintenance 1L ES-SCLC 4D-MT 4D-R125 X-linked retinitis pigmentosa RG7935 prasinezumab Parkinson's RG7461 simlukafusp alfa combos solid tumors CHU PTH1 recep. ago hypoparathyroidism RG6147 - geographic atrophy Venclexta + AMG176 AML CHU - hyperphosphatemia RG6367 SPK-7001 choroideremia RG7601 Venclexta ± azacitidine r/r MDS RG7774 - retinal disease New Molecular Entity (NME) CardioMetabolism Venclexta + gilteritinib r/r AML Additional Indication (AI) Neuroscience IONIS ASO factor B geographic atrophy *Individualized Neoantigen Specific Immunotherapy; T=Tecentriq Oncology / Hematology Ophthalmology RG-No - Roche/Genentech SQZ - SQZ Biotechnology managed Immunology Other CHU - Chugai managed NOV - Novimmune managed 2 Status as of October 15, 2020 Infectious Diseases IONIS – IONIS managed 4D-MT - 4D-MT managed Roche Group development pipeline

Phase III (12 NMEs + 34 AIs) Registration (5 NMEs + 11 AIs)

RG6013 Hemlibra mild to moderate hemophilia A RG7446/ Tecentriq bTMB-high RG6264 Phesgo 1 Perjeta + Herceptin FDC SC HER2+ BC 1L NSCLC tiragolumab + T + chemo 1L SCLC RG6268 or entrectinib ROS1+ Gavreto (pralsetinib) 1 RET+ NSCLC RG6396 tiragolumab + T 1L PD-L1+ NSCLC Venclexta r/r MM t(11:14) Gavreto (pralsetinib) 2 RET+ MTC RG6058 RG7601 tiragolumab + T locally advanced esophageal cancer Venclexta + azacitidine 1L MDS Tecentriq Dx+ 1 1L sq + non-sq NSCLC RG7446 tiragolumab + T .stage III unresectable 1L NSCLC RG7853 Alecensa ALK+ NSCLC adj Tecentriq+ Avastin 1 1L HCC RG6107 crovalimab PNH RG1569 Actemra COVID-19 pneumonia RG7601 Venclexta + azacitidine 1L AML RG6114 mPI3K alpha inh 1L HR+ mBC RG1569 Actemra + remdesivir COVID-19 pneumonia RG7853 Alecensa 1LNSCLC Dx+ RG6171 SERD (3) ER+/HER2- mBC RG3648 Xolair food allergy Xolair 3 nasal polyps RG3648 ipatasertib + abiraterone 1L CRPC RG7159 Gazyva lupus nephritis Xolair 2 asthma home use ipatasertib + chemo 1L TNBC/HR+ BC RG7413 etrolizumab Crohn’s Xofluza 1 influenza RG7440 ipatasertib + fulvestrant + palbociclib 1L HR+ mBC Xofluza influenza, hospitalized pts Xofluza 1 influenza, high risk RG6152 ipatasertib + Tecentriq + taxane 1L TNBC RG6152 Xofluza influenza, pediatric (0-1 year) Xofluza influenza post exposure prophylaxis RG7596 Polivy 1L DLBCL Xofluza influenza direct transmission Xofluza 2 influenza, pediatric (1-12 yrs) RG6413+ 3 Tecentriq NSCLC adj REGN-COV2 nABs SARS-CoV2 prophylaxis RG1594 Ocrevus short infusion RMS & PPMS RG6412 Tecentriq NMIBC, high risk RG6168 Enspryng (satralizumab) 1 NMOSD RG1450 gantenerumab Alzheimer’s Tecentriq RCC adj RG7916 Evrysdi (risdiplam) 1 SMA RG6042 tominersen Huntington’s Tecentriq + cabozantinib advanced RCC port delivery system with ranibizumab . wAMD Tecentriq + cabozantinib 2L NSCLC 1 RG6321 port delivery system with ranibizumab . DME Approved in US, filed in EU T ± chemo SCCHN adj RG7446 port delivery system with ranibizumab DR 2 Filed in US Tecentriq HER2+ BC neoadj faricimab DME 3 T + capecitabine or carbo/gem 1L TNBC RG7716 Filed in US, approved in EU faricimab wAMD T + paclitaxel TNBC adj New Molecular Entity (NME) CardioMetabolism T + nab-paclitaxel TNBC neoadj Additional Indication (AI) Neuroscience T + Avastin HCC adj Oncology / Hematology Ophthalmology Immunology Other T ± chemo 1L mUC Infectious Diseases T=Tecentriq

3 Status as of October 15, 2020 NME submissions and their additional indications Projects in phase II and III

Port Delivery System tiragolumab + TLR7 ago (3) RG7907+ RG6321 with ranibizumab RG6058 Tecentriq (T) + CpAM (2) RG7854 wAMD 1L PD-L1+ cervical ca HBV Xofluza ✓ rhPTX-2 RG6413+ REGN-COV2 Crovalimab tiragolumab + T FGFR1 x KLB MAb RG6152 influenza, pediatric RG6107 RG6058 RG7992 RG6354 (PRM-151) SARS-CoV2 prophylaxis PNH 1L PD-L1+ NSCLC NASH (1-12 yrs) RG6412 IPF Xofluza ✓ REGN-COV2 tiragolumab + T rhPTX-2 RG6413+ tominersen ralmitaront RG6152 influenza post-exposure COVID-19+ RG6042 RG6058 locally adv esophageal RG7906 RG6354 (PRM-151) RG6412 Huntington’s schizophrenia prophylaxis adult-ambulatory cancer myelofibrosis REGN-COV2 tiragolumab + T microdystrophin Evrysdi (risdiplam) RG6413+ gantenerumab ST2 MAb RG7916 COVID-19+ RG1450 RG6058 Stage III unresectable 1L RG6356 SRP-9001 RG6149 SMA (EU) RG6412 Alzheimer‘s asthma adult-hospitalized NSCLC DMD Gavreto Xofluza semorinemab etrolizumab mPI3K alpha inh Anti-tryptase RG6396 (pralsetinib) ✓ RG6152 influenza, pediatric RG7413 RG6114 RG6100 (Tau MAb ) RG6173 Crohn’s 1L HR+ BC asthma RET+ NSCLC (0-1 year) Alzheimer’s Gavreto Xofluza Xofluza iNeST** prasinezumab fenebrutinib RG6396 (pralsetinib) ✓* RG6152 RG6152 RG6180 RG7935 RG7845 influenza, hospitalized direct transmission oncology Parkinson’s autoimmune diseases RET+ MTC ipatasertib + Port Delivery System ipatasertib + fulv + faricimab SERD(3) RG7880 IL22-Fc RG7440 abiraterone RG7716 RG6321 with ranibizumab RG7440 palbociclib RG6171 DME ER+/HER2- mBC inflammatory diseases 1L CRPC DME 1L HR+ mBC tiragolumab + ipatasertib + Port Delivery System ipatasertib + chemo faricimab SERD(3) RG7440 RG7716 RG6058 Tecentriq RG7440 Tecentriq + taxane RG6171 RG6321 with ranibizumab 1L TNBC / HR+ BC wAMD neoadjuvant HR+ BC 1L SCLC 1L TNBC DR 2020 2021 2022 2023 and beyond

✓ Indicates submission to health authorities has occurred New Molecular Entity (NME) CardioMetabolism Unless stated otherwise submissions are planned to occur in US and EU Additional Indication (AI) Neuroscience *US submission only Oncology / Hematology Ophthalmology Immunology Other Infectious Diseases **Individualized Neoantigen Specific Immunotherapy 4 Status as of October 15, 2020 AI submissions for existing products Projects in phase II and III

New Molecular Entity (NME) Immunology Neuroscience Additional Indication (AI) Infectious Diseases Ophthalmology Oncology / Hematology CardioMetabolism Other

Tecentriq + Avastin RG7446 HCC adj

Xolair ✓ Tecentriq SC RG3648 RG7446 Asthma home use NSCLC

Actemra Tecentriq RG1569 RG7446 COVID-19 pneumonia HER2+ BC neoadj Cotellic + Tecentriq + Tecentriq + paclitaxel Gazyva RG7421 Zelboraf ✓ RG7446 RG7159 TNBC adj lupus nephritis 1L+ BRAFm melanoma Tecentriq + nab-paclitaxel Actemra + remdesivir Tecentriq Venclexta RG7446 RG1569 RG7446 RG7601 TNBC neoadj COVID-19 pneumonia High risk NMIBC r/r MM t(11:14) Hemlibra Tecentriq ± chemo Tecentriq + chemo Venclexta + carfilzomib RG7446 RG6013 Mild to moderate RG7446 RG7601 1L mUC SCCHN adj r/r MM t(11:14) hemophilia A (EU) Tecentriq + capecitabine Tecentriq + Avastin ✓ Rozlytrek (BFAST) Xolair Venclexta + azacitidine RG7446 RG6268 RG3648 RG7446 or carbo/gem RG7601 1L HCC 1L NSCLC ROS1+ Food allergy 1L MDS TNBC Venclexta +azacitidine ✓ Tecentriq (BFAST) Tecentriq Tecentriq + cabozantinib Venclexta + fulvestrant RG7601 RG7446 RG7446 RG7446 RG7601 1L AML 1L NSCLC bTMB-high NSCLC adj adv RCC 2L HR+BC

Alecensa (BFAST) ✓ Polivy Tecentriq Tecentriq + cabozantinib Alecensa RG7853 RG7596 RG7446 RG7446 RG7853 1L NSCLC ALK+ 1L DLBCL RCC adj 2L NSCLC ALK+ NSCLC adj

2020 2021 2022 2023 and beyond 5 Status as of October 15, 2020 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU Major pending approvals 2020

US EU China Japan-Chugai

Xolair Enspryng (satralizumab) CellCept Polivy RG3648 nasal polyps RG6168 NMOSD RG99 lupus nephritis RG7596 r/r DLBCL Filed Sept 2019 Filed Aug 2019 Filed Aug 2018 Filed June 2020 Alecensa (BFAST) Tecentriq Avastin RG7853 1L NSCLC ALK+ RG7446 1L non-sq + sq NSCLC Dx+ RG405 1L/2L glioblastoma Filed Jan 2020 Filed Nov 2019 Filed Jan 2019 Ocrevus Xofluza MabThera RG1594 Short infusion RMS & PPMS RG6152 influenza RG105 CLL and FL Filed Feb 2020 Filed Nov 2019 Filed Apr 2019 Xofluza Xofluza Tecentriq +Avastin RG6152 post exposure prophylaxis RG6152 influenza, high risk RG7446 1L HCC Filed March 2020 Filed Nov 2019 Filed Jan 2020 Xofluza Xofluza Evrysdi (risdiplam) RG6152 influenza, pediatric (1-12 yrs) RG6152 post exposure prophylaxis RG7916 SMA Filed March 2020 Filed Nov 2019 Filed March 2020 Venclexta+ azacitidine Tecentriq +Avastin Enspryng (satralizumab) RG7601 1L AML RG7446 1L HCC RG6168 NMOSD Filed May 2020 Filed Jan 2020 Filed April 2020 Gavreto (pralsetinib) Phesgo FDC SC Xofluza RG6396 RET+ MTC RG6264 Her2+BC RG6152 influenza Filed July 2020 Filed Jan 2020 Filed May 2020 Venclexta+ azacitidine Xofluza RG7601 1L AML RG6152 influenza, high risk New Molecular Entity (NME) CardioMetabolism Filed May 2020 Filed May 2020 Additional Indication (AI) Neuroscience Gavreto (pralsetinib) Hemlibra RG6396 RET+ NSCLC RG6013 Hemophilia A Oncology / Hematology Ophthalmology Filed May 2020 Filed June 2020 Immunology Other Gazyva Infectious Diseases RG7159 1L FL and r/r FL Sept 2020 FDC = fixed-dose combination Tecentriq RG7446 1L non-sq + sq NSCLC Dx+ Filed Sept 2020 Tecentriq + pemetrexed RG7446 1L non-sq NSCLC Filed Sept 2020 6 Status as of October 15, 2020 Major granted approvals 2020

US EU China Japan-Chugai

Venclexta+Gazyva Polivy Kadcyla Rozlytrek (entrectinib) RG7601 1L CLL RG7596 r/r DLBCL RG3502 HER2+ eBC RG6268 ROS1+ NSCLC Mar 2020 January 2020 Jan 2020 Feb 2020 Tecentriq + Avastin Venclexta+Gazyva Tecentriq + chemo Alecensa RG7446 1L HCC RG7601 1L CLL RG7446 1L extensive stage SCLC RG7853 r/r ALK+ ALCL May 2020 Mar 2020 Feb 2020 Feb 2020 Tecentriq Ocrevus Rituxan RG7446 1L non-sq + sq NSCLC Dx+ RG1594 Short infusion RMS & PPMS RG105 thrombocytopenic purpura May 2020 May 2020 Feb 2020 Cotellic + Zelboraf+ Tecentriq Rozlytrek (entrectinib) Enspryng (satralizumab) RG7421 1L+ BRAFm melanoma RG6268 ROS1+ NSCLC RG6168 NMOSD May 2020 Aug 2020 June 2020 Phesgo Rozlytrek (entrectinib) Kadcyla RG6264 (Perjeta+Herceptin) FDC SC RG6268 NTRK+ tumor-agnostic RG3502 HER2+ eBC adj Her2+BC June 2020 Aug 2020 Aug 2020 Evrysdi (risdiplam) Tecentriq +Avastin RG7916 SMA RG7446 HCC Aug 2020 Sept 2020 Enspryng (satralizumab) RG6168 NMOSD Aug 2020 Gavreto (pralsetinib) RG6396 RET+ NSCLC Aug 2020

New Molecular Entity (NME) CardioMetabolism Additional Indication (AI) Neuroscience Oncology / Hematology Ophthalmology Immunology Other Infectious Diseases

FDC = fixed-dose combination 7 Status as of October 15, 2020 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Spark

8 Hemlibra Factor VIII mimetic for treatment of hemophilia A

Hemophilia A patients Hemophilia A pediatric patients Indication with inhibitors to factor VIII with inhibitors to factor VIII

Phase III Phase III Phase/study HAVEN 1 HAVEN 2 # of patients N=118 N=88 Patients on episodic treatment prior to study entry: Patients on prophylactic or episodic treatment prior to study entry: . ARM A: Hemlibra prophylaxis . Cohort A: Hemlibra prophylaxis qw . ARM B: Episodic treatment (no prophylaxis) . Cohort B: Hemlibra prophylaxis q2w Design Patients on prophylaxis prior to study entry: . Cohort C: Hemlibra prophylaxis q4w . ARM C: Hemlibra prophylaxis Patients on episodic treatment previously on non-interventional study:

. ARM D: Hemlibra prophylaxis Hemophilia Primary endpoint . Number of bleeds over 24 weeks . Number of bleeds over 52 weeks

. FPI Q4 2015, recruitment completed in arms A and B Q2 2016 . FPI Q3 2016, recruitment completed Q2 2017 . Primary and all secondary endpoints met Q4 2016 . Positive interim data in Q2 2017 . Data published in NEJM 2017; 377:809-818 . FPI cohorts B/C Q4 2017 . Full primary data at ASH 2018 Status . Data published in Blood 2019;134(24):2127-2138

. Data presented at ISTH 2017, updated data presented at ASH 2017 . Filed in US and EU in Q2 2017; granted accelerated assessment (EMA) and priority review (FDA) . Approved in US Q4 2017 and EU Q1 2018

CT Identifier NCT02622321 NCT02795767 9 In collaboration with Chugai ASH=American Society of Hematology; ISTH=International Society on Thrombosis and Haemostasis; NEJM=New England Journal of Medicine Hemlibra Factor VIII mimetic for treatment of hemophilia A

Hemophilia A patients Hemophilia A patients with and without inhibitors to Factor VIII, Indication without inhibitors to factor VIII dosing every 4 weeks

Phase III Phase III Phase/study HAVEN 3 HAVEN 4

# of patients N=135 N=46 Patients on FVIII episodic treatment prior to study entry: Multicenter, open-label, non-randomized study to assess the efficacy, . ARM A: Hemlibra prophylaxis qw safety, pharmacokinetics, and pharmacodynamics of Hemlibra . ARM B: Hemlibra prophylaxis q2w administered every 4 weeks. Design . ARM C: Episodic FVIII treatment; switch to Hemlibra prophylaxis . Part 1: Pharmacokinetic (PK) run-in part (N=6) possible after 24 weeks . Part 2: Expansion part (N=40) Patients on FVIII prophylaxis prior to study entry:

. ARM D: Hemlibra prophylaxis qw Hemophilia Primary endpoint . Number of bleeds over 24 weeks . Number of bleeds over 24 weeks

. FPI Q3 2016, recruitment completed Q2 2017 . FPI Q1 2017, recruitment completed Q2 2017 . Study met primary and key secondary endpoints Q4 2017 . PK run-in data at ASH 2017 . FDA granted Breakthrough Therapy Designation April 2018 . Positive interim analysis outcome reported Q4 2017 . Data presented at WFH 2018 . Data presented at WFH 2018 Status . Filed in US (priority review) and EU in Q2 2018 . Interim data filed in US and EU in Q2 2018 . Data published in NEJM 2018; 379: 811-822 . Data published in Lancet Haematology 2019 Jun;6(6):e295-e305 •Approved in US Q4 2018 and EU Q1 2019

CT Identifier NCT02847637 NCT03020160 10 In collaboration with Chugai ASH=American Society of Hematology; WFH=World Federation of Hemophilia; NEJM=New England Journal of Medicine Hemlibra Factor VIII mimetic for treatment of hemophilia A

Hemophilia A mild to moderate patients without inhibitors to Factor Indication Hemophilia A patients with and without inhibitors to Factor VIII VIII

Phase III Phase III Phase/study HAVEN 5 HAVEN 6

# of patients N=85 N=70 Patients with Hemophilia regardless of FVIII inhibitor status on Multicenter, open-label study to evaluate the safety, efficacy, prophylactic or episodic treatment prior to study entry: pharmacokinetics, and pharmacodynamics of Hemlibra in patients with Design • Arm A: emicizumab prophylaxis qw mild or moderate Hemophilia A without FVIII inhibitors • Arm B: emicizumab prophylaxis q4w

• Arm C: No prophylaxis (control arm) Hemophilia . Number of bleeds over 24 weeks . Safety and efficacy Primary endpoint

. FPI Q2 2018 . FPI Q1 2020 . Recruitment completed Q1 2019 Status . Filed in China Q2 2020

CT Identifier NCT03315455 NCT04158648

In collaboration with Chugai 11 Alecensa New CNS-active inhibitor of anaplastic lymphoma kinase

Treatment-naïve Indication Adjuvant ALK+ NSCLC ALK+ advanced NSCLC

Phase III Phase III Phase/study ALEX ALINA

# of patients N=286 N=255

. ARM A: Alecensa 600mg BID . ARM A: Alecensa 600 mg BID Design . ARM B: Crizotinib 250mg BID . ARM B: Platinum-based chemotherapy

Primary endpoint . Progression-free survival . Disease-free survival Oncology

. Recruitment completed Q3 2015 . FPI Q3 2018 . Primary endpoint met Q1 2017 . Data presented at ASCO 2017, 2018, ESMO 2017, 2018 Status . Data published in NEJM 2017; 377:829-838 . CNS data presented at ESMO 2017 . Final PFS and updated OS presented at ESMO 2019 . Approved in US Q4 2017 (priority review) and in EU Q4 2017

CT Identifier NCT02075840 NCT03456076

In collaboration with Chugai 12 NSCLC=non-small cell lung cancer; ASCO=American Society of Clinical Oncology; NEJM=New England Journal of Medicine; ESMO=European Society for Medical Oncology Kadcyla First ADC for HER2-positive breast cancer

HER2-positive early breast cancer Indication high-risk patients

Phase III Phase/study KATHERINE

# of patients N=1,484

. ARM A: Kadcyla 3.6mg/kg q3w . ARM B: Herceptin

Design Oncology . Invasive disease-free survival Primary endpoint

. Recruitment completed Q4 2015 • Stopped at pre-planned interim data analysis for efficacy Q4 2018 • Data presented at SABCS 2018 Status • BTD granted by FDA in Q1 2019 • US filling completed under RTOR Q1 2019 and filed in EU Q1 2019 • Approved in US Q2 2019 and in EU Q4 2019 • Data published in NEJM 2019; 380:617-628

CT Identifier NCT01772472

In collaboration with ImmunoGen, Inc. 13 ADC=antibody drug conjugate; SABCS=San Antonio Breast Cancer Symposium; RTOR=Real time oncology review; ORR=Objective Response Rate Perjeta First-in-class HER2 dimerization inhibitor

Indication Adjuvant HER2-positive breast cancer Neoadjuvant HER2-positive breast cancer

Phase III Phase III Phase/study APHINITY IMpassion050

# of patients N=4,803 N=453

. ARM A: Perjeta (840mg loading, 420 q3w) + Herceptin for 52 weeks . ARM A: ddAC Herceptin/Perjeta + paclitaxel followed by surgery and plus chemotherapy (6-8 cycles) chemotherapy . ARM B: Placebo + Herceptin (52 weeks) plus chemotherapy (6-8 . ARM B: ddAC Herceptin/Perjeta + chemotherapy +Tecentriq followed by surgery and chemotherapy +Tecentriq

Design cycles) Oncology

. Invasive disease-free survival (IDFS) . Pathologic complete response (pCR) Primary endpoint

. Primary endpoint met Q1 2017 . FPI Q4 2018 . Data presented at ASCO 2017 and published in NEJM 2017; 377:122-131 . Recruitment completed Q3 2020 Status . Filed in US and EU Q3 2017 . Approved in US Q4 2017 (priority review) and EU Q2 2018 . Six year IDFS data presented at SABCS 2019

CT Identifier NCT01358877 NCT03726879 14 ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC=fluorouracil, epirubicin and cyclophosphamide; ASCO=American Society of Clinical Oncology; SABCS=San Antonio Breast Cancer Symposium First Perjeta SABCS=San Antonio Breast Cancer SymposiumSABCS=SanCancerBreastAntonio CT Identifier Status Primary endpoint Design # Phase/study Indication of patients - in - class HER2 dimerization inhibitor ...... neoadjuvant administrationin combinationwithchemotherapyin thesubcutaneous Fixed ARM ARM B: ARM A: Data presentedat 2019SABCS endpointPrimarymet completed Q4 2018 Recruitment Trough( SerumConcentration - dose Perjeta Herceptin (H)(FDC) of (P) combinationand for FDC PH FDC of P IV+H /adjuvantsetting IV+chemotherapy SC+chemotherapy Q3 2019 NCT03493854 FeDeriCa Phase Phase III Ctrough N=500 HER2 ) of Pertuzumab During Cycle of Pertuzumab) 7 Cycle During - positive early breast cancer subcutaneousco . Filed inin EUFiled Jan2020 USQ42019& . Approved in ...... US Q22020 US ARM ARM B: ARM A: Data presentedat 2020 ESMO preferred 85% Final analysis patientscompleted,FDC FPI Q42018 PH FDC who preferredPercentageSC PH PH IV followed by FDC followed by FDC PH IV SC FDC FDC followedSC by IV - formulation PHranceSCa NCT03674112 Phase Phase II N=160 SC 15

Oncology Perjeta/Kadcyla and Tecentriq Her2 targeted agents in combination with anti-PD-L1

Indication Metastatic and locally advanced early breast cancer (HER2-positive)

Phase/study Phase I

# of patients N=76

. Cohort 1A (mBC): Tecentriq plus Perjeta plus Herceptin . Cohort 1B (mBC): Tecentriq plus Kadcyla1 . Cohort 1F (mBC): Tecentriq plus Perjeta plus Herceptin plus docetaxel Design . Cohort 2A (eBC): Tecentriq plus Perjeta plus Herceptin . Cohort 2B (eBC): Tecentriq plus Kadcyla1 . 1 Cohort 2C (expansion on cohort 1B): Tecentriq plus Kadcyla Oncology

. Safety Primary endpoint

. FPI Q4 2015 Status . Recruitment completed Q2 2018

CT Identifier NCT02605915

1 In collaboration with ImmunoGen, Inc. 16 eBC=early breast cancer; mBC=metastatic breast cancer Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer

1L non-squamous and squamous NSCLC Indication 1L non-squamous NSCLC PD-L1-selected patients

Phase III Phase III Phase III Phase/study IMpower150 IMpower132 IMpower110

# of patients N=1,202 N=568 N=570

. ARM A: Tecentriq plus paclitaxel plus . ARM A: Tecentriq plus carboplatin or cisplatin . ARM A: Tecentriq monotherapy carboplatin plus pemetrexed . ARM B: NSq: carboplatin or cisplatin plus . ARM B: Tecentriq plus Avastin plus paclitaxel . ARM B: Carboplatin or cisplatin plus pemetrexed Design plus carboplatin pemetrexed Sq: carboplatin or cisplatin plus gemcitabine . ARM C: Avastin plus paclitaxel plus

carboplatin Oncology

Primary endpoint . Progression-free survival and overall survival . Progression-free survival and overall survival . Overall survival

. Study met co-primary endpoint of PFS in Q4 . FPI Q2 2016 . IMpower111 consolidated into IMpower110 Q3 2017 and OS in Q1 2018 . Recruitment completed Q2 2017 2016 . PFS data presented at ESMO IO 2017 and OS . Study met co-primary endpoint of PFS in Q2 . Recruitment completed Q1 2018 at ASCO 2018 2018 . Study met primary endpoint in PD-L1 high Status . Filed in US Q1 2018 (priority review) and EU . Data presented at WCLC 2018 (IC3/TC3) Q3 2019 (Q1 2018) . Data presented at ESMO and ESMO-IO 2019 . Data published in NEJM 2018; 378:2288-2301 . Filed in EU and US (priority review) Q4 2019 . Approved in US Q4 2018 and EU Q1 2019 . Approved in US Q2 2020

CT Identifier NCT02366143 NCT02657434 NCT02409342

NSCLC=non-small cell lung cancer; NSq=non-squamous; Sq=squamous; ESMO=European Society for Medical Oncology; ASCO=American Society of Clinical Oncology; NEJM=New England Journal 17 of Medicine; WCLC=World Conference on Lung Cancer Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer

Indication 1L extensive-stage SCLC

Phase III Phase/study Phase Ib IMpower133

# of patients N=400 N=62

. ARM A: Tecentriq plus carboplatin plus etoposide . Carboplatin and etoposide +/- Tecentriq followed by maintenance . ARM B: Placebo plus carboplatin plus etoposide Tecentriq plus Venclexta Design

Primary endpoint . Progression-free survival and overall survival . Safety and efficacy Oncology

. FPI Q2 2016 . FPI Q3 2020 . Orphan drug designation granted by FDA Q3 2016 . Study met endpoints of OS and PFS in Q2 2018 Status . Primary data presented at WCLC 2018 . Data published in NEJM 2018; 379:2220-2229 . Filed with the US and EU Q3 2018 . Approved in US Q1 2019 and EU Q3 2019

CT Identifier NCT02763579 NCT04422210

SCLC=small cell lung cancer; NEJM=New England Journal of Medicine; WCLC=World Conference on Lung Cancer 18 Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer

Indication Adjuvant NSCLC Neoadjuvant NSCLC

Phase III Phase III Phase/study IMpower010 IMpower030

# of patients N=1,280 N=450

Following adjuvant cisplatin-based chemotherapy . ARM A: Tecentriq + platinum-based chemotherapy . ARM A: Tecentriq . ARM B: Platinum-based chemotherapy Design . ARM B: Best supportive care

Primary endpoint . Disease-free survival . Major pathological response and event free survival Oncology

. FPI Q3 2015 . FPI Q2 2018 . Trial amended from PD-L1+ selected patients to all-comers Status . FPI for all-comer population Q4 2016 . Recruitment completed Q3 2018

CT Identifier NCT02486718 NCT03456063

NSCLC=non-small cell lung cancer 19 Tecentriq Anti-PD-L1 cancer immunotherapy – lung cancer

2L NSCLC previously treated with an immune Indication 1L NSCLC Stage IV NSCLC checkpoint inhibitor

Phase/stud Phase II/III Phase Ib/III Phase III y B-FAST IMscin001 CONTACT-01 # of N=660 N=375 N=350 patients

. Cohort A: ALK+ (Alecensa) Part Ib . ARM A: Tecentriq plus cabozantinib . Cohort B: RET+ (Alecensa) . Dose finding, Tecentriq SC followed by . ARM B: Docetaxel . Cohort C: bTMB-high (Tecentriq) Tecentriq IV Design . Cohort D: ROS1+ (Rozlytrek) Part III . Cohort E: BRAF+ (Zelboraf plus Cotellic plus . 2L NSCLC non inferiority of Tecentriq SC vs Tecentriq) Tecentriq IV Oncology

Primary . Cohort A/B: Objective response rate . Observed concentration of Tecentriq in serum . Overall survival endpoint . Cohort C: Progression-free survival at cycle 1

. FPI Q3 2017 . FPI Q4 2018 . FPI Q3 2020 . Recruitment completed for cohort A Q3 2018 and cohort C Q3 2019 Status . Study met primary endpoint in cohort A (ALK+) Q3 2019; presented at ESMO 2019 . ALK+ Alecensa (cohort A) filed in US Q1 2020 CT NCT03178552 NCT03735121 NCT04471428 Identifier NSCLC=non-small cell lung cancer; ESMO=European Society for Medical Oncology 20 Tecentriq Anti-PD-L1 cancer immunotherapy – SCCHN/hematology/melanoma First-line BRAFv600 mutation-positive Adjuvant squamous cell carcinoma of the Indication Relapsed or refractory AML metastatic or unresectable locally advanced head and neck melanoma

Phase III Phase III Phase/study Phase I IMvoke010 IMspire150 TRILOGY1

# of patients N=400 N=21 N=500

. ARM A: Tecentriq 1200mg q3w . Tecentriq plus anti-CD47 Double-blind, randomized, placebo-controlled . ARM B: Placebo study Design . ARM A: Tecentriq plus Cotellic plus Zelboraf2 . ARM B: Placebo plus Cotellic plus Zelboraf2

Primary endpoint . Event-free survival and overall survival . Safety and efficacy . Progression-free survival Oncology

. FPI Q1 2018 . FPI Q4 2019 . FPI Q1 2017 . Recruitment completed Q1 2020 . Recruitment completed Q2 2018 . Primary endpoint met Q4 2019 . Data presented at AACR 2020 Status . Data published in Lancet;395(10240):1835- 1844 . Filed in US Q2 2020 under Project Orbis3 . Approved in US Q3 2020

CT Identifier NCT03452137 NCT03922477 NCT02908672

SCCHN=squamous cell carcinoma of the head and neck; AML=acute myeloid leukemia; 1In collaboration with Exelixis; 2Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 3 21 Project Orbis=FDA framework for concurrent submission and review of oncology products among international partners; AACR=American Association for Cancer Research Tecentriq Anti-PD-L1 cancer immunotherapy – UC

High-risk non-muscle-invasive Indication 1L metastatic urothelial carcinoma bladder cancer

Phase III Phase III Phase/study IMvigor130 ALBAN

# of patients N=1,200 N=614

. ARM A: Tecentriq plus gemcitabine and carboplatin or cisplatin . ARM A: BCG induction and maintenance . ARM B: Tecentriq monotherapy . ARM B: Tecentriq+ BCG induction and maintenance Design . ARM C: Placebo plus gemcitabine and carboplatin or cisplatin

Primary endpoint . Progression-free survival, overall survival and safety . Recurrence-free survival Oncology

. FPI Q3 2016 . FPI Q4 2018 . FPI for arm B (amended study) Q1 2017 Status . Recruitment completed Q3 2018 . Study met co-primary endpoint of PFS Q3 2019 . Data presented at ESMO 2019

CT Identifier NCT02807636 NCT03799835

UC=urothelial carcinoma; BCG=Bacille Calmette-Guérin 22 Tecentriq Anti-PD-L1 cancer immunotherapy – renal cell cancer

Advanced renal cell carcinoma after immune checkpoint inhibitor Indication Adjuvant renal cell carcinoma treatment

Phase III Phase III Phase/study IMmotion010 Contact-031

# of patients N=778 N=500

. ARM A: Tecentriq monotherapy . ARM A: Tecentriq plus cabozantinib . ARM B: Observation . ARM B: cabozantinib Design

. Disease-free survival . Progression-free survival and overall survival

Primary endpoint Oncology

. FPI Q1 2017 . FPI Q3 2020 Status . Recruitment completed Q1 2019

CT Identifier NCT03024996 NCT04338269

1In collaboration with Exelixis 23 Tecentriq Anti-PD-L1 cancer immunotherapy – CRC and HCC

Indication 2/3L metastatic colorectal cancer 1L hepatocellular carcinoma Adjuvant hepatocellular carcinoma

Phase III Phase III Phase/study Phase I IMbrave150 IMbrave050

# of patients N=84 N=501 N=662

Open-label, single-arm, two-stage study . ARM A: Tecentriq plus Avastin . ARM A: Tecentriq plus Avastin with Cotellic plus Tecentriq plus Avastin . ARM B: Sorafenib . ARM B: Active surveillance • Stage 1: Safety run-in Design • Stage 2: Dose-expansion with two cohorts:

–Expansion Oncology –Biopsy

Primary endpoint . Safety . Overall survival and progression free survival . Recurrence-Free Survival (RFS)

. FPI Q3 2016 . FPI Q1 2018; recruitment completed Q1 2019 . FPI Q4 2019 . Recruitment completed Q3 2018 . Data presented at ESMO Asia 2019 . Data presented at ESMO 2019 . US filing completed under RTOR Q1 2020; filed in Status EU Q1 2020 . Data published in NEJM 2020;382:1894-1905 . Approved in US Q2 2020 . Positive CHMP opinion Q3 2020

CT Identifier NCT02876224 NCT03434379 NCT04102098 24 Cotellic in collaboration with Exelixis; ESMO=European Society for Medical Oncology; NEJM=New England Journal of Medicine; RTOR=Real time oncology review; CHMP=Committee for Medicinal Products for Human Use in the European Medicines Agency Tecentriq Anti-PD-L1 cancer immunotherapy – breast cancer

Previously untreated metastatic Indication triple negative breast cancer

Phase III Phase III Phase III Phase/study IMpassion130 IMpassion131 IMpassion132

# of patients N=900 N=540 N=572

. ARM A: Tecentriq plus nab-paclitaxel . ARM A: Tecentriq plus paclitaxel . ARM A: Tecentriq plus capecitabine or . ARM B: Placebo plus nab-paclitaxel . ARM B: Placebo plus paclitaxel carbo/gem Design . ARM B: Placebo plus capecitabine or carbo/gem

. Progression-free survival and overall survival . Progression-free survival . Overall survival Oncology Primary endpoint (co-primary endpoint)

. Recruitment completed Q2 2017 . FPI Q3 2017 . FPI Q1 2018 . Study met co-primary endpoint of PFS in both . Recruitment completed Q3 2019 PDL1+ and ITT populations Jul 2018 . Study did not meet primary endpoint Q3 2020 . Primary PFS and interim OS data presented at . Data presented at ESMO 2020 Status ESMO 2018 and ASCO 2019 . Data published in NEJM 2018; 379:2108-2121 . US accelerated approval Q1 2019 . Approved in EU Q3 2019

CT Identifier NCT02425891 NCT03125902 NCT03371017

ESMO=European Society for Medical Oncology; ASCO=American Society of Clinical Oncology; NEJM=New England Journal of Medicine 25 Tecentriq Anti-PD-L1 cancer immunotherapy – breast cancer

Indication Neoadjuvant triple negative breast cancer Adjuvant triple negative breast cancer

Phase III Phase III Phase/study IMpassion031 IMpassion030

# of patients N=324 N=2,300

. ARM A: Tecentriq plus nab-paclitaxel . ARM A: Tecentriq + paclitaxel followed by AC followed by Tecentriq . ARM B: Placebo plus nab-paclitaxel + AC, followed by Tecentriq maintenance . ARM B: Placebo + paclitaxel followed by AC followed by placebo

Design Oncology

Primary endpoint . Percentage of participants with pathologic complete response (pCR) . Invasive Disease Free Survival

. FPI Q3 2017 . FPI Q3 2018 . Recruitment completed Q2 2018 . Q1 2019 IDMC recommendation to expand study to recruit 120 additional Status patients (all comers and PDL1-positive). Recruitment completed for additional patients Q3 2019 . Study met primary endpoint Q2 2020 . Data presented at ESMO 2020

CT Identifier NCT03197935 NCT03498716 IDMC=Independent data monitoring committee; ESMO=European Society for Medical Oncology 26 Tecentriq Anti-PD-L1 cancer immunotherapy – ovarian cancer

Advanced gynecological cancers Indication Front-line ovarian cancer and triple negative breast cancer

Phase III Phase/study Phase Ib IMaGYN050

# of patients N=1,300 N=48

. ARM A: Tecentriq plus carboplatin plus paclitaxel plus Avastin . Part 1: Dose finding Tecentriq plus rucaparib (CO-338)1 . ARM B: Carboplatin plus paclitaxel plus Avastin . Part 2: Expansion Tecentriq plus rucaparib (CO-338)1

Design Oncology Primary endpoint . Progression-free survival and overall survival (co-primary endpoint) . Safety

. FPI Q1 2017 . FPI Q2 2017 . Recruitment completed Q1 2019 Status . Primary endpoint not met Q2 2020 . Data presented at ESMO 2020

CT Identifier NCT03038100 NCT03101280

1Rucaparib in collaboration with Clovis; ESMO=European Society for Medical Oncology 27 Venclexta Novel small molecule Bcl-2 selective inhibitor – CLL

Untreated CLL patients with Indication Relapsed or refractory CLL Untreated fit CLL patients coexisting medical conditions

Phase III Phase III Phase III Phase/study CLL14 MURANO CristaLLo

# of patients N=432 N=391 N=165

. ARM A: Venclexta plus Gazyva . ARM A: Venclexta plus Rituxan . ARM A: Venclexta plus Gazyva . ARM B: Chlorambucil plus Gazyva . ARM B: Rituxan plus bendamustine . ARM B: Fludarabine + cyclophosphamide Design + Rituxan or bendamustine + Rituxan

. Progression-free survival . Progression-free survival . MRD negativity rate in peripheral blood at Oncology Primary endpoint 15 months

. Study met primary endpoint at pre-specified . Study met primary endpoint at interim analysis . FPI Q2 2020 interim analysis Q4 2018 . Data presented at ASH 2017 . BTD granted by FDA Q1 2019 . Filed in US Q4 2017 and EU Q1 2018 . US filing completed under RTOR Q1 2019 . Data published in NEJM 2018; 378:1107–20 Status . Filed in EU Q2 2019 . Updated data presented at ASCO 2018 and ASH . Data presented at ASCO 2019 and ASH 2019 2019 . Data published in NEJM 2019; 380:2225-2236 . Approved in US Q2 2018 (priority review) . Approved US Q2 2019 and EU Q1 2020 . EU approval Q4 2018

CT Identifier NCT02242942 NCT02005471 NCT04285567

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute CLL=chronic lymphocytic leukemia; ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology; RTOR=Real time oncology review; 28 NEJM=New England Journal of Medicine; MRD=Minimal Residual Disease Venclexta Novel small molecule Bcl-2 selective inhibitor – MM

Indication Relapsed or refractory multiple myeloma

Phase III Phase/study Phase I Phase Ib/II CANOVA

# of patients N=166 N=120 N=244

. Dose escalation cohort: . Venclexta plus carfilzomib plus dexamethasone in . Venclexta plus dexamethazone vs pomalidomide Venclexta dose escalation t(11;14) positive r/r MM plus dexamethasone in t(11;14) positive r/r MM . Safety expansion cohort (t11:14): Design Venclexta expansion . Combination:

Venclexta plus dexamethasone Oncology

Primary endpoint . Safety and maximum tolerated dose . Safety, objective response rate, PK, PD . Progression-free survival

. FPI Q4 2012 . FPI Q1 2017 . FPI Q4 2018 . Data presented at ASCO 2015 Status . Updated data presented at ASCO 2016 and ASH 2016

CT Identifier NCT01794520 NCT02899052 NCT03539744

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute; 29 MM=multiple myeloma; ASCO=American Society of Clinical Oncology; ASH=American Society of Hematology Venclexta Novel small molecule Bcl-2 selective inhibitor – AML

Indication Treatment-naïve AML not eligible for standard induction therapy

Phase III Phase III Phase/study Viale-A Viale-C

# of patients N=443 N=175

• ARM A: Venclexta plus azacitidine . ARM A: Venclexta plus low-dose cytarabine • ARM B: Azacitidine • ARM B: Low-dose cytarabine Design

. Overall survival and percentage of participants with complete . Overall survival Oncology Primary endpoint remission

. FPI Q1 2017 . FPI Q2 2017 . Study met dual primary endpoints Q1 2020 . Study did not meet primary endpoint Q1 2020 . Data presented at EHA 2020 . Primary and additional 6 month overall survival data presented at ASCO . Data published NEJM 2020 Aug 13;383(7):617-629 2020 Status

. Filed in US and EU Q2 2020

CT Identifier NCT02993523 NCT03069352

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute 30 AML=acute myeloid leukemia; EHA=European Hematology Association Venclexta Novel small molecule Bcl-2 selective inhibitor – AML

Indication Treatment-naïve AML not eligible for standard induction therapy

Phase/study Phase Ib Phase Ib/II

# of patients N=212 N=92

. Venclexta (dose escalation) plus decitabine . Venclexta (dose escalation) plus low-dose cytarabine . Venclexta (dose escalation) plus azacitidine . Venclexta (dose escalation) plus decitabine plus posaconazole

Design Oncology Primary endpoint . Safety . Safety, PK, PD and efficacy

. FPI Q4 2014 . FPI Q1 2015 . Initial data presented at ASH 2015, updated data presented at ASCO 2016 . Initial data presented at ASCO 2016, updated data presented at ASH and ASCO 2018 2016 and ASH 2017 Status . Breakthrough Therapy Designation granted by FDA Q1 2016 . Breakthrough Therapy Designation granted by FDA Q3 2017 . Data published in Blood. 2019 Jan 3;133(1):7-17

. Filed in US Q3 2018 . US accelerated approval Q4 2018

CT Identifier NCT02203773 NCT02287233

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute; 31 AML=acute myeloid leukemia; ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology Venclexta Novel small molecule Bcl-2 selective inhibitor – AML

Indication Relapsed or refractory AML Relapsed or refractory hematological malignancies

Phase/study Phase I Phase I

# of patients N=52 N=86

. Venclexta in combination with gilteritinib . Venclexta plus AMG176 dose escalation . Dose expansion phase to confirm safety and preliminary RPTD

Design Oncology Primary endpoint . Dose and composite complete remission (CRc) Rate . Maximum tolerated dose and safety

. FPI Q4 2018 . FPI Q2 2019 . Initial data presented at ASH 2019 . Study on clinical hold Status

CT Identifier NCT03625505 NCT03797261

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute; 32 AML=acute myeloid leukemia; ASH=American Society of Hematology; RPTD =recommended phase II dose Venclexta Novel small molecule Bcl-2 selective inhibitor – MDS

Relapsed or refractory myelodysplastic Newly diagnosed higher-risk Indication Treatment-naive myelodysplastic syndromes syndromes myelodysplatic syndrome

Phase/stud Phase III Phase Ib Phase II y VERONA

# of N=70 N=129 N=500 patients

Cohort 1: . ARM A: Venclexta 400 mg plus azacitidine . ARM A: Venclexta plus azacitidine . ARM A: Venclexta 400 mg . ARM B: Venclexta 800 mg plus azacitidine . ARM B: Placebo plus azacitidine . ARM B: Venclexta 800 mg . ARM C: Azacitidine Design Cohort 2:

. ARM A: Venclexta plus azacitidine Oncology Study expansion: . Venclexta or Venclexta plus azacitidine

Primary . Safety, efficacy, PK and PD . Overall response rate . Complete remission rate and overall survival endpoint

. FPI Q1 2017 . FPI Q1 2017 . FPI Oct 2020 Status . Data presented at ASH 2019 CT NCT02966782 NCT02942290 NCT04401748 Identifier

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute 33 MDS=myelodysplastic syndromes; ASH=American Society of Hematology Venclexta Novel small molecule Bcl-2 selective inhibitor – breast cancer

Indication ≥2L HR+ breast cancer

Phase II Phase/study VERONICA

# of patients N=103

. ARM A: Venclexta plus fulvestrant . ARM B: Fulvestrant Design

Primary endpoint . Clinical benefit lasting equal or more than 24 weeks Oncology

. FPI Q3 2018 Status

CT Identifier NCT03584009

Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute 34 Polivy (polatuzumab vedotin) ADC targeting CD79b to treat B cell malignancies

Relapsed or refractory Indication 1L DLBCL FL and DLBCL

Phase III Phase/study Phase Ib/II POLARIX

# of patients N=329 N=875

. PIb: Dose escalation . ARM A: Polatuzumab vedotin plus R-CHP Design . PhII: Polatuzumab vedotin plus BR vs. BR . ARM B: R-CHOP . PhII expansion: Polatuzumab vedotin plus Gazyva (non-randomized)

Primary endpoint . Safety and response by PET/CT . Progression-free survival Oncology . FPI Q4 2014 . FPI Q4 2017 . PRIME Designation (Q2 2017) and Breakthrough Therapy Designation . Recruitment completed Q2 2019 (Q3 2017) granted for r/r DLBCL Status . Pivotal randomized Ph2 in r/r DLBCL presented at ASH 2017 . Filed in US and EU Q4 2018; US priority review granted Q1 2019 . Approved in US Q2 2019 and in EU Jan 2020 . Published in J Clin Oncol. 2020 Jan 10;38(2):155-165

CT Identifier NCT02257567 NCT03274492

In collaboration with Seagen Inc. ADC=antibody–drug conjugate; DLBCL=diffuse large B cell lymphoma; FL=follicular lymphoma; r/r=relapsed or refractory; ASH=American Society of Hematology; BR=bendamustine and Rituxan; R-CHP=Rituxan, cyclophosphamide, hydroxydoxorubicin, prednisone; R-CHOP=Rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone 35 Polivy (polatuzumab vedotin) ADC targeting CD79b to treat B cell malignancies

Indication Relapsed or refractory FL or DLBCL

Phase/study Phase I/II Phase I/II

# of patients N=134 N=128

• Dose escalation cohort: . Dose escalation cohort: Polatuzumab vedotin plus Gazyva plus Venclexta1 Polatuzumab vedotin plus Gazyva plus lenalidomide • Expansion cohort DLBCL: . Expansion cohort DLBCL: Design Polatuzumab vedotin plus Rituxan plus Venclexta1 Polatuzumab vedotin plus Rituxan plus lenalidomide • Expansion cohort FL: . Expansion cohort FL:

Polatuzumab vedotin plus Gazyva plus Venclexta1 Polatuzumab vedotin plus Gazyva plus lenalidomide Oncology

Primary endpoint . Percentage of participants with CR . Percentage of participants with CR

. FPI Q1 2016 . FPI Q1 2016 Status . FL not developed further due to portfolio priorities . Interim data in FL presented at ASCO, EHA and ICML 2019 . Primary data presented at ASH 2019

CT Identifier NCT02611323 NCT02600897

In collaboration with Seagen Inc.; 1Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute ADC=antibody–drug conjugate; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; CR=complete response; ASH=American Society of Hematology; EHA=European Hematology Association; ICML=International Conference on Malignant Lymphoma 36 Rozlytrek (entrectinib) CNS-active and selective inhibitor of NTRK/ROS1

Locally Advanced or Metastatic tumors with Locally Advanced or Metastatic tumors with Pediatric tumors with NTRK 1/2/3, ROS-1 Indication ROS1 gene rearrangement NTRK1/2/3 gene rearrangement or ALK rearrangement

Phase II Phase II Phase I/Ib Phase/study STARTRK2 STARTRK2 STARTRK - NG

# of patients N~300 total N~300 total N~80 Single arm with Baskets based on tumor type Single arm with Baskets based on tumor type Single arm with Baskets based on tumor type and genomic alteration status and genomic alteration status and genomic alteration status Design

. Objective response rate . Objective response rate . Maximum tolerated dose (MTD) and Primary endpoint Oncology recommended phase II dose (RP2D)

. FPI Q1 2016 . FPI Q1 2016 . FPI Q2 2016 . Data presented at WCLC 2018 . Data presented at ESMO 2018 . Initial data presented at ASCO 2019

Status . Breakthrough Therapy Designation granted by FDA (Q2 2017), PRIME designation granted by EMA (Q1 2018) and Sakigake Designation granted by MHLW (Q4 2017) for NTRK fusion-positive, locally advanced or metastatic solid tumors . Filed in US Q4 2018 and EU Q1 2019 . Approved in US Q3 2019 and EU Q3 2020 . Published in Lancet Oncol. 2020 Feb;21(2):261-271 and 271-282

CT Identifier NCT02568267 NCT02568267 NCT02650401

WCLC=World Conference on Lung Cancer; ESMO=European Society for Medical Oncology; ASCO=American Society of Clinical Oncology; NTRK=neurotrophic receptor tyrosine kinase; 37 PRIME= priority medicines Gavreto (pralsetinib, RG6396) Highly selective RET inhibitor

RET+ NSCLC, thyroid cancer and Indication 1L RET fusion-positive, metastatic NSCLC other advanced solid tumors

Phase I/II Phase III Phase/study ARROW AcceleRET Lung

# of patients N=647 N=250

. Part 1: Gavreto 30-600mg dose-escalation . Arm A: Gavreto 400mg Design . Part 2: Gavreto 400mg dose expansion . Arm B: Platinum-based chemotherapy +/- pembrolizumab

Primary endpoint . Safety and efficacy . Progression-free survival Oncology . Data presented at ASCO (NSCLC) and ESMO (medullary thyroid cancer) . Study initiated in Q1 2020 2020 Status . Filed in US and EU for RET fusion-positive NSCLC and US for RET- mutant medullary thyroid cancer and RET fusion-positive thyroid cancer . Approved in US September 2020 in RET fusion-positive NSCLC

CT Identifier NCT03037385 NCT04222972

In collaboration with Blueprint Medicines NSCLC=non-small cell lung cancer; ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology 38 Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells

Primary-progressive Indication Relapsing multiple sclerosis (RMS) multiple sclerosis (PPMS)

Phase III Phase III Phase III Phase/study OPERA I OPERA II ORATORIO

# of patients N=821 N=835 N=732 96-week treatment period: 96-week treatment period: 120-week treatment period: . ARM A: Ocrelizumab 2x300 mg iv . ARM A: Ocrelizumab 2x300 mg iv . ARM A: Ocrelizumab 2x300 mg iv every 24 weeks Design followed by 600 mg iv every 24 weeks followed by 600 mg iv every 24 weeks . ARM B: Placebo . ARM B: Interferon -1a . ARM B: Interferon -1a

. Annualized relapse rate at 96 weeks . Annualized relapse rate at 96 weeks . Sustained disability progression versus placebo by Expanded Primary endpoint

versus Rebif versus Rebif Disability Status Scale (EDSS) Neuroscience

. Primary endpoint met Q2 2015, OLE ongoing . Primary endpoint met Q3 2015 . Primary data presented at ECTRIMS 2015 . Primary data presented at ECTRIMS 2015, updated data . Updated data presented at AAN and ECTRIMS 2017, AAN and EAN 2018 presented at AAN and ECTRIMS 2017, AAN and EAN 2018 Status . Data published in NEJM 2017; 376:221-234 . Data published in NEJM 2017; 376:209-220

. Approved in US Q1 2017 and EU Q1 2018

CT Identifier NCT01247324 NCT01412333 NCT01194570

OLE=Open label extension; ECTRIMS=European Committee for Treatment and Research in Multiple Sclerosis; AAN=Annual Meeting of the American Academy of Neurology; EAN=European 39 Academy of Neurology; NEJM=New England Journal of Medicine Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells

Relapsing and primary progressive multiple sclerosis (RMS & Indication Primary progressive multiple sclerosis (PPMS) PPMS)

Phase IIIb Phase IIIb Phase/study ENSEMBLE PLUS ORATORIO-HAND

# of patients N=1225 N ~ 1000 • Substudy of ongoing phase IIIb, open-label, single-arm ENSEMBLE 120-week treatment period: study . ARM A: Ocrelizumab 600mg IV every 24 weeks Design • Shorter two-hour infusion time . ARM B: Placebo

. Safety, measured by the proportion of patients with IRRs following the . Time to upper limb disability progression confirmed for at least 12 weeks first randomised 600 mg infusion (frequency/severity assessed during Primary endpoint and 24-hours post infusion) Neuroscience

• Filed in US and EU Q1 2020 . FPI Q3 2019 • Approved in EU Q2 2020 Status • Data published Neurol, Neuroimmunol and Neuroinflamm Sept 2020; 7(5), e807

CT Identifier NCT03085810 NCT04035005

40 Ocrevus (ocrelizumab, RG1594) Humanized mAb selectively targeting CD20+ B cells

Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS)

Phase IIIb Phase IIIb Phase/study GAVOTTE MUSETTE

# of patients N ~ 699 N ~ 786 120-week treatment period: 120-week treatment period: . ARM A: Ocrelizumab 600mg IV every 24 weeks . ARM A: Ocrelizumab 600mg IV every 24 weeks Design . ARM B: Ocrelizumab 1200mg if body weight <75kg or 1800mg if body . ARM B: Ocrelizumab 1200mg if body weight <75kg or 1800mg if body weight > or equal to 75kg every 24 weeks weight > or equal to 75kg every 24 weeks

. Superiority of Ocrelizumab higher dose versus approved dose on . Superiority of Ocrelizumab higher dose versus approved dose on Primary endpoint

composite confirmed disability progression (cCDP) composite confirmed disability progression (cCDP) Neuroscience . FPI expected Q4 2020 . FPI expected Q4 2020 Status

CT Identifier NCT04548999 NCT04544436

41 Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier

Indication Spinal muscular atrophy

Phase II/III Phase II/III Phase II Phase/study FIREFISH SUNFISH JEWELFISH

# of patients N=21 (Part 1), 41 (Part 2) N=51 (Part 1), 180 (Part 2) N=174 Open-label study in infants with type 1 spinal Randomized, double-blind, placebo-controlled . Open-label single arm study in adult and muscular atrophy: study in adult and pediatric patients with type 2 pediatric patients with previously treated SMA Design . Part 1 (dose-finding): At least 4 weeks or type 3 spinal muscular atrophy: type 1, 2 and 3 . Part 2 (confirmatory): 24 months . Part 1 (dose-finding): At least 12 weeks . Part 2 (confirmatory): 24 months .

Primary endpoint . Safety, tolerability, PK, PD and efficacy . Safety, tolerability, PK, PD and efficacy Safety, tolerability and PK/PD Neuroscience . Recruitment completed for part 2 Q4 2018 . Recruitment completed for part 2 Q3 2018 . FPI Q1 2017 . 12 month data from Part 1 presented at AAN, . 12 month data from Part 1 presented at AAN, . Data presented at WMS 2017, AAN 2018, WMS CureSMA and EAN 2019; 16 month data CureSMA and EAN 2019; 16 month data 2018, CureSMA 2019, WMS 2019 and presented at WMS 2019 presented at WMS 2019 CureSMA2020 Status . Study met primary endpoint in part 2 Jan 2020 . Study met primary endpoint in part 2 Q4 2019 . Recruitment completed Q1 2020 . Part 2 1-year data presented at AAN 2020 and . Part 2 Data presented at SMA Europe 2020 part 1 2-year data at WMS 2020

. Orphan drug designation granted by FDA Q1 2017 and EU Q1 2019, PRIME designation in Q4 2018; filed in US Q4 2019; approved in US Q3 2020

CT Identifier NCT02913482 NCT02908685 NCT03032172 In collaboration with PTC Therapeutics and SMA Foundation 42 SMN=survival motor neuron; AAN=American Academy of Neurology; WMS=World Muscle Society; EAN=European Academy of Neurology; PRIME=priority medicines Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier

Indication Spinal muscular atrophy

Phase II Phase/study RAINBOWFISH

# of patients N=25 Open-label, single-arm, multicenter study in infants aged from birth to 6 weeks who have been genetically diagnosed with SMA but are not yet presenting with symptoms Design

. Proportion of participants with two copies of the SMN2 gene (excluding the known SMN2 gene modifier mutation c.859G>C) and baseline Neuroscience Primary endpoint CMAP>=1.5 millivolt who are sitting without support

. FPI Q3 2019 Status

CT Identifier NCT03779334

In collaboration with PTC Therapeutics and SMA Foundation 43 SMN=survival motor neuron; CMAP=compound muscle action potential Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody

Indication Neuromyelitis optica spectrum disorder (NMOSD)

Phase III Phase III Phase/study Sakura Star Sakura Sky

# of patients N=95 N=70 (adults); N=6 (adolescents) Satralizumab as monotherapy: Add-on therapy of satralizumab: • Group A: Satralizumab 120mg SC monthly • Group A: Satralizumab 120mg SC monthly Design • Group B: Placebo SC monthly • Group B: Placebo SC Both arms on top of baseline therapies: azathioprine, mycophenolate mofetil or oral corticosteroids

Primary endpoint •Efficacy (time to first relapse) and safety, PD, PK . Efficacy (time to first relapse) and safety, PD, PK Neuroscience . Primary endpoint met Q4 2018 . FPI Q3 2017 . Data presented at ECTRIMS 2019 . Primary endpoint met Q3 2018 . Published in Lancet Neurology 2020; 19(5): 402-412 . Data presented at ECTRIMS 2018 and AAN 2019 Status . Published in NEJM 2019; 381:2114-2124 . BTD granted Q4 2018 . Filed in EU Q3 2019; US acceptance of filing Q4 2019, . Approved in US Q3 2020

CT Identifier NCT02073279 NCT02028884

*Trials managed by Chugai (Roche opted-in) ECTRIMS=European Committee for Treatment and Research in Multiple Sclerosis; AAN=American Academy of Neurology; NEJM=New England Journal of Medicine 44 Gazyva (obinutuzumab) Immunology development program

Indication Lupus nephritis

Phase II Phase III Phase/study NOBILITY REGENCY

# of patients N=126 N=252

. ARM A: Obinutuzumab 1000mg IV plus mycophenolate mofetil / . ARM A: Obinutuzumab 1000 mg IV (six doses through Week 52) plus mycophenolic acid mycophenolate mofetil . ARM B: Placebo IV plus mycophenolate mofetil / mycophenolic acid . ARM B: Obinutuzumab 1000 mg IV (five doses through Week 52) plus Design mycophenolate mofetil

. ARM C: Placebo IV plus mycophenolate mofetil Immunology Primary endpoint . Percentage of participants who achieve complete renal response (CRR) . Percentage of participants who achieve complete renal response (CRR)

. Recruitment completed Q4 2017 . FPI Q3 2020 . Primary endpoint met Q2 2019 Status . Breakthrough therapy designation granted by the FDA Q3 2019 . Data presented at ASN and ACR 2019

CT Identifier NCT02550652 NCT04221477

In collaboration with Biogen 45 ASN=American Society of Nephrology; ACR=American College of Rheumatology Actemra/RoActemra (RG-1569) Interleukin 6 receptor inhibitor

Indication Adult hospitalised with severe COVID-19 pneumonia

Phase III Phase III Phase/study COVACTA1 REMDACTA2

# of patients N=450 N=500

. Arm A: tocilizumab plus standard of care . Arm A: remdesivir plus tocilizumab . Arm B: placebo plus standard of care . Arm B: remdesivir plus placebo

Design Immunology . Clinical status assessed using 7-Category Ordinal Scale (Day 28) . Time to hospital discharge or ready for discharge Primary endpoint . Primary endpoint not met Q3 2020

. FPI Q1 2020 . FPI Q2 2020 Status . LPI Q2 2020

CT Identifier NCT04320615 NCT04409262

1In collaboration with US Biomedical Advanced Research and Development Authority (BARDA); 2In collaboration with Gilead Sciences, Inc. 46 Actemra/RoActemra (RG-1569) Interleukin 6 receptor inhibitor

Indication Adult hospitalised with severe COVID-19 pneumonia

Phase II Phase III Phase/study MARIPOSA EMPACTA

# of patients N=100 N=379

. Arm A: 8 mg/kg tocilizumab plus standard of care Conducted in sites known to provide critical care to underserved and . Arm B: 4mg/kg tocilizumab plus standard of care minority populations that often do not have access to clinical trials

Design . Arm A: tocilizumab plus standard of care

. Arm B: placebo plus standard of care Immunology . Pharmacodynamics and pharmacokinetics . Cumulative proportion of participants requiring mechanical ventilation Primary endpoint by day 28

. FPI Q2 2020 . FPI Q2 2020 Status . LPI Q2 2020 . Primary endpoint met Q3 2020

CT Identifier NCT04363736 NCT04372186

47 Xolair Humanized mAb that selectively binds to IgE

Indication Chronic rhinosinusitis with nasal polyps Food allergy

Phase III Phase III Phase III Phase/study POLYP 1 POLYP 2 OUtMATCH1

# of patients N=138 N=127 N=225 Adult patients with chronic rhinosinusitis Adult patients with chronic rhinosinusitis with • Xolair by subcutaneous injection either every 2 with nasal polyps (CRSwNP) who have had nasal polyps (CRSwNP) who have had an weeks or every 4 weeks for 16 to 20 weeks an inadequate response to SOC: inadequate response to SOC: Design • ARM A: Xolair every 2 wks or every 4 wks • ARM A: Xolair every 2 wks or every 4 wks • ARM B: Placebo • ARM B: Placebo

. Change from baseline in average daily . Change from baseline in average daily nasal • Number of participants who successfully Immunology nasal congestion score (NCS) at week 24 congestion score (NCS) at week 24 consume ≥600 mg of peanut protein without Primary endpoint . Change from baseline in nasal polyp score . Change from baseline in nasal polyp score (NPS) dose-limiting symptoms (NPS) to week 24 to week 24

. FPI Q4 2017 . FPI Q4 2017 • FPI July 2019 . Recruitment completed Q3 2018 . Recruitment completed Q3 2018 Status . Co-primary endpoints met Q2 2019 . Co-primary endpoints met Q2 2019 . Filed in US Q4 2019 . Approved in the EU Q3 2020

CT Identifier NCT03280550 NCT03280537 NCT03881696 48 In collaboration with Novartis; 1 Sponsor of the study is the National Institute of Allergy and Infectious Diseases (NIAID) Xofluza (baloxavir marboxil, RG6152, S-033188 ) Small molecule, novel CAP-dependent endonuclease inhibitor

Indication Influenza

Phase III Phase III Phase/study CAPSTONE-1 CAPSTONE-2

# of patients N=1,436 N=2,184

. Randomized, double-blind study of a single dose of Xofluza . Randomized, double-blind study of a single dose of Xofluza compared with compared with placebo or Tamiflu 75 mg twice daily for 5 days in placebo or Tamiflu 75 mg twice daily for 5 days in patients with influenza at otherwise healthy patients with influenza high risk of influenza complications

Design Diseases

Primary endpoint . Time to alleviation of symptoms . Time to improvement of influenza symptoms

. FPI Q4 2016, recruitment completed Q1 2017 . FPI Q1 2017, recruitment completed Q1 2018 Infectious . Primary endpoint met Q3 2017 . Primary endpoint met Q3 2018 . Filed in US Q2 2018 (priority review), approval Q4 2018 . Data presented at IDweek 2018 Status . Data published in NEJM 2018; 379:913-923 . Filed in US Q1 2019, approval Q4 2019 . Filed in EU Q4 2019 . Filed in EU Q4 2019 . Data published in Lancet Infectious Diseases 2020 Jun 8;S1473- 3099(20)30004-9

CT Identifier NCT02954354 NCT02949011 In collaboration with Shionogi & Co., Ltd. 49 NEJM=New England Journal of Medicine Xofluza (baloxavir marboxil, RG6152, S-033188 ) Small molecule, novel CAP-dependent endonuclease inhibitor

Indication Influenza

Phase III Phase III Phase III Phase/study FLAGSTONE (hospitalised patients) miniSTONE 1 (0-1 year old) miniSTONE 2 (1-12 years old )

# of patients N=366 N=30 N=176

• Xofluza + neuraminidase inhibitor vs placebo • Xofluza on Day 1 (based on body weight and age) • Xofluza vs Tamiflu in healthy pediatric + neuraminidase inhibitor in hospitalized in healthy pediatric patients from birth to <1 year patients 1 to <12 years of age with influenza- patients with influenza with influenza-like symptoms like symptoms Design

Primary endpoint . Time to clinical improvement . Safety . Safety

. FPI Jan 2019 • FPI Q1 2019 • FPI Q4 2018 Diseases Infectious . Recruitment completed Q1 2020 • Recruitment completed Q1 2019 • Primary endpoint met Q2 2019 Status • Data presented at OPTIONS X 2019 • Filed in US Q1 2020 • Data published in Pediatric Infectious Disease 2020 Aug;39(8):700-705

CT Identifier NCT03684044 NCT03653364 NCT03629184 In collaboration with Shionogi & Co., Ltd. 50 Xofluza (baloxavir marboxil, RG6152, S-033188) Small molecule, novel CAP-dependent endonuclease inhibitor

Indication Influenza

Phase III Phase IIIb Phase/study BLOCKSTONE CENTERSTONE

N= 752 N= 3,160 # of patients

. Post exposure prophylaxis to prevent disease onset in household . Reduction of direct transmission of influenza from otherwise healthy contacts. Used after known exposure to infected person. patients to household contacts . Household contacts treated with Xofluza vs placebo . Patients treated with Xofluza vs placebo Design

. Percentage of household contacts who developed clinical influenza . Percentage of household contacts who are PCR-positive for influenza by Primary endpoint day 5 post randomization of index patients

. Study met primary endpoint Q2 2019 Infectious Diseases Infectious . Data presented at OPTIONS X 2019 Status . FPI Q4 2019 . Filed in US Q1 2020 . Data published in NEJM 2020 Jul 8. doi:10.1056/NEJMoa1915341 CT Identifier JapicCTI-184180 NCT03969212

In collaboration with Shionogi & Co., Ltd. 51 PCR=Polymerase chain reaction; NEJM=New England Journal of Medicine Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Spark

52 Ipatasertib (RG7440, GDC-0068) Highly selective small molecule inhibitor of Akt

Prostate cancer previously treated with Indication 1L castration-resistant prostate cancer Advanced prostate cancer and solid tumors androgen receptor-targeted therapy

Phase III Phase/study Phase Ib Phase Ib IPATential150

# of patients N=1,100 N=54 N=50

. ARM A: Ipatasertib plus abiraterone . Ipatasertib plus rucaparib . Ipatasertib plus Tecentriq plus docetaxel . ARM B: Placebo plus abiraterone Stage 1: Dose escalation in advanced breast, ovarian and prostate cancer Design

. Stage 2: Dose expansion in prostate cancer Oncology . Radiographic progression-free survival (rPFS) • Safety and efficacy • Safety and efficacy Primary endpoint in patients with PTEN loss tumors and overall population

. FPI Q2 2017 • FPI Q2 2019 • FPI Q3 2020 . Recruitment completed Jan 2019 Status . Study met co-primary endpoint in rPFS in patients with PTEN loss tumors Q2 2020 . Data presented at ESMO 2020

CT Identifier NCT03072238 NCT03840200 NCT04404140

In collaboration with Array BioPharma 53 ESMO=European Society for Medical Oncology TNBC= In Highly Ipatasertib (RG7440, GDC CT Identifier Status Primary endpoint Design # Phase/study Indication collaboration of triple patients - negative with selective Array Array breast BioPharma ...... Cohort . . Cohort cancer 2020 primaryCohort A(TNBC)met endpointnot Q3 presentedat 2020 ESMO primaryCohortmet,(HR+) B endpointnot data Q1 A cohort Q1 andcohortcompleted B Recruitment2019 FPI Q12018 Progression ARM B: ARM A: ARM B: ARM A: ; ASCO=American Society ASCO=American ; 1L TNBC TNBC 1L B: B: A: Placebo+paclitaxel Placebo+paclitaxel Ipatasertib+paclitaxel Ipatasertib+paclitaxel Dx+ HR+ mBCHR+ (N=201): Dx+ Dx+ 1L (N=249):TNBC small - free 2020 and IPATunity130 survival NCT03337724 Phase Phase III N=450 HR+ molecule breast of Clinical cancer Oncology - 0068) ; AACR=American ; inhibitor ...... Aug 8.pii:S1470 Data publishedLancet Oncology in 2018 Data completed Q1 2016 Recruitment Progression B:ARM Placebo+paclitaxel A: ARM Ipatasertib+paclitaxel Association presented - of Akt free NCT02162719 for at ASCO at ASCO 2017 1L TNBC 1L Phase Phase II - survival LOTUS N=124 2045(17)30450 Cancer Research; and - 3 ESMO=European Society for Medical for Society ESMO=European ASCO ASCO 2017 . . . . . Data presented at AACR Data presentedat AACR 2019 FPI Q12018 Safety paclitaxel B:ARM Ipatasertib+Tecentriq+nab +paclitaxel A: ARM Ipatasertib+Tecentriq and efficacy NCT03800836 Phase Phase Oncology N=202 TNBC Ib - 54

Oncology Ipatasertib (RG7440, GDC-0068) Highly selective small molecule inhibitor of Akt

Indication 1L HR+ mBC 1L TNBC

Phase Ib/III Phase III Phase/study IPATunity150 IPATunity170

# of patients N=370 N=1,155

. ARM A: Ipatasertib plus fulvestrant and palbociclib Ipatasertib plus Tecentriq plus paclitaxel: . ARM B: Placebo plus fulvestrant and palbociclib . ARM A: PD-L1 negative . ARM B: PD-L1 positive

Design Oncology Primary endpoint . Progression free survival in ITT and in patients with PIK3CA/AKT1/PTEN . Progression free survival and overall survival altered tumors . FPI Q4 2019 in Phase Ib part . FPI Q4 2019 Status

CT Identifier NCT04060862 NCT04177108

In collaboration with Array BioPharma 55 Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT

Indication 1L NSCLC PD-L1 TPS>50% 1L ES-SCLC

Phase III Phase III Phase/study SKYSCRAPER-01 SKYSCRAPER-02

# of patients N=500 N=424

. Arm A: Tiragolumab plus Tecentriq . Arm A: Tiragolumab plus Tecentriq, carboplatin and etoposide . Arm B: Placebo plus Tecentriq . Arm B: Placebo plus Tecentriq, carboplatin and etoposide

Design Oncology

. Overall survival and progression free survival . Overall survival and progression free survival Primary endpoint

. FPI Q1 2020 . FPI Q1 2020 Status

CT Identifier NCT04294810 NCT04256421

NSCLC=Non-small cell lung cancer; ES-SCLC=Extensive stage small cell lung cancer 56 Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT

Metastatic and/or recurrent PD-L1+ Indication Stage III unresectable 1L NSCLC cervical cancer

Phase III Phase II Phase/study SKYSCRAPER-03 SKYSCRAPER-04

# of patients N=800 N=160

. Arm A: Tiragolumab plus Tecentriq for up to 12 months . Arm A: Tiragolumab plus Tecentriq . Arm B: Durvalumab for up to 12 months . Arm B: Tecentriq

Design Oncology

. Progression-free survival . Objective Response Rate (ORR) Primary endpoint

. FPI Q3 2020 . FPI Q2 2020 Status

CT Identifier NCT04513925 NCT04300647

NSCLC=Non-small cell lung cancer 57 Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT

Indication Locally advanced esophageal cancer 1L esophageal cancer

Phase III Phase III Phase/study SKYSCRAPER-07 SKYSCRAPER-08

# of patients N=750 N=500

. Arm A: Tiragolumab plus Tecentriq . Arm A: Tiragolumab plus Tecentriq plus cisplatin and paclitaxel . Arm B: Tecentriq plus placebo . Arm B: Placebo plus placebo plus cisplatin and paclitaxel . Arm C: Placebo plus placebo

Design Oncology

. Progression-free survival (A vs C) . Overall survival and progression-free survival Primary endpoint . Overall survival (A vs C, hierarchical, B vs C hierarchical)

. FPI Q3 2020 . FPI expected Q4 2020 Status

CT Identifier NCT04543617 NCT04540211

NSCLC=Non-small cell lung cancer 58 Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT

R/R Multiple Myeloma (MM) or R/R B-cell Indication Solid tumors NSCLC NHL

Phase II Phase/study Phase I Phase l CITYSCAPE

# of patients N=400 N=135 N=52

. Phase Ia: Dose escalation and . Arm A: Tecentriq plus tiragolumab . Phase Ia: Tiragolumab monotherapy expansion of tiragolumab . Arm B: Tecentriq monotherapy . Phase Ib: Tiragolumab plus daratumumab (r/r . Phase Ib: Dose escalation and MM) or rituximab (r/r NHL) expansion Tecentriq plus tiragolumab Design . Phase Ib: Chemo combinations with

tiragolumab (cis, carbo, pem, pac, Oncology etoposide)

. Safety, tolerability, PK variability and . Overall response rate and progression-free . Safety, tolerability, PK/PD and preliminary Primary endpoint preliminary efficacy survival efficacy

. FPI Q2 2016 . FPI Q3 2018 . FPI Q2 2019 Status . Data presented at AACR 2020 . Recruitment completed Q2 2019 . Data presented at ASCO 2020

CT Identifier NCT02794571 NCT03563716 NCT04045028

NSCLC=Non-small cell lung cancer; r/r=Relapsed refractory; NHL=Non-Hodgkin's lymphoma; ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research 59 Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultanously

Indication Relapsed or refractory Non-Hodgkin’s lymphoma Non-Hodgkin’s lymphoma

Phase/study Phase I Phase Ib Phase Ib

Part I: 15-60 # of patients N=700 N=140 Part II: ~66-104 Cohort 1: Single-agent dose escalation Dose escalation and expansion . Part I: Dose-finding for the combination of study . Arm A: glofitamab + Tecentriq glofitamab plus G/R CHOP in r/r indolent NHL . Initial dose escalation . Arm B: glofitamab + Polivy . Part II: Dose expansion glofitamab plus G/R- . Expansion cohort in r/r DLBCL CHOP or R-CHOP in 1L DLBCL Design . Expansion cohort in r/r FL

All patients will receive pretreatment with a Oncology single dose of Gazyva (1000mg) Cohort 2: glofitamab + Gazyva (i.e. continuous treatment with Gazyva)

Primary endpoint . Safety . Safety . Safety

. FPI Q1 2017 . FPI Q2 2018 . FPI Q1 2018 Status . Data presented at ASH 2018, ICML and . Data presented at ASH 2019 ASH 2019, and EHA 2020

CT Identifier NCT03075696 NCT03533283 NCT03467373

DLBCL=diffuse large B cell lymphoma; FL=Follicular lymphoma; ASH=American Society of Hematology; EHA=European Hematology Association; ICML=International Conference on Malignant 60 Lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; R=Rituxan/MabThera; G=Gazyva Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultanously

Relapsed/refractory DLBCL and High-Grade Large B-Cell Indication Relapsed/refractory DLBCL Lymphoma

Phase/study Phase Ib Phase III

# of patients N=20 N=270

. Glofitamab plus gemcitabine and oxaliplatin, followed by up to 4 cycles . Arm A: glofitamab plus gemcitabine and oxaliplatin, followed by up to 4 of glofitamab monotherapy cycles of glofitamab monotherapy . A single dose of obinutuzumab will be administered 7 days prior to the . Arm B: Rituxan in combination with gemcitabine and oxaliplatin Design first dose of glofitamab A single dose of obinutuzumab will be administered 7 days prior to the

first dose of glofitamab Oncology

. Safety . Overall survival Primary endpoint

. FPI Q2 2020 . FPI expected early 2021 Status

CT Identifier NCT04313608 NCT04408638

61 Mosunetuzumab (CD20/CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultanously

Indication 3L+ DLBCL & 3L+ FL & ibrutinib R/R MCL 1L DLBCL R/R DLBCL & FL

Phase/study Phase I Phase Ib/II Phase Ib

# of patients N=746 N=160 N=262

. Dose escalation study of mosunetuzumab as . Mosunetuzumab plus CHOP . Mosunetuzumab plus polatuzumab vedotin single agent and in combination with . Mosunetuzumab plus CHP plus polatuzumab Tecentriq vedotin Design . Expansion cohorts for r/r FL, r/r DLBCL and

ibrutinib r/r MCL Oncology

. Safety, tolerability, dose/schedule, PK, and . Safety/tolerability and response . Safety/tolerability and response Primary endpoint response rates

. FPI Q3 2015 . FPI Q1 2019 . FPI Q3 2018 . First data in r/r NHL presented at ASH 2018 Status and 2019 . BTD granted by FDA Q2 2020

CT Identifier NCT02500407 NCT03677141 NCT03671018

FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; r/r=relapsed/refractory; NHL=non-Hodgkin’s lymphoma; CHOP=cyclophosphamide, doxorubicin, vincristine, and 62 prednisone; CHP=cyclophosphamide, doxorubicin, and prednisone); ASH=American Society of Hematology Mosunetuzumab (CD20/CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultanously

Indication 1L DLBCL & 2L DLBCL following 1L induction R/R 2L+ FL

Phase/study Phase I Phase Ib

# of patients N=92 N=27

. Cohort A: Mosunetuzumab monotherapy (after a response to prior . Mosunetuzumab plus lenalidomide systemic chemotherapy) . Cohort B: Mosunetuzumab monotherapy (1L treatment in elderly/frail)

Design Oncology

. Safety/tolerability and response . Safety/tolerability and response Primary endpoint

. FPI Q2 2019 – Cohort B . FPI Q3 2020 Status . FPI Q3 2019 – Cohort A

CT Identifier NCT03677154 NCT04246086

FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; r/r=relapsed/refractory 63 PI3K alpha inhibitor (RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor

PIK3CA mutant solid tumors and metastatic Indication PIK3CA-mutant HR+ mBC ER+ HER2-neg breast cancer

Phase III Phase/study Phase I INAVO120

# of patients N=400 N=156

. Arm A: GDC-0077 plus palbociclib plus fulvestrant Monotherapy and in combination with SoC (letrozole; letrozole plus . Arm B: Placebo plus palbociclib plus fulvestrant palbociclib; fulvestrant) • Stage 1: Dose escalation

Design • Stage 2: Expansion Oncology

. Progression-free survival • Safety, tolerability and PK Primary endpoint

. FPI Q1 2020 • FPI Q4 2016 Status • Preclinical/molecule discovery data presented at AACR 2017 • Data presented at SABCS 2019 CT Identifier NCT04191499 NCT03006172

AACR=American Association for Cancer Research; SABCS=San Antonio Breast Cancer Symposium 64 SERD (3) (RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator

Indication Metastatic ER+ HER2-neg breast cancer ER+ HER2-neg Stage I-III operable breast cancer

Phase/study Phase I Phase I

# of patients N=220 N=75

. Dose escalation and expansion at recommended phase II dose (RP2D) . Open-label, pre-operative administration . Single agent and in combination with palbociclib and/or luteinizing . Dose escalation hormone−releasing hormone (LHRH) agonist

Design Oncology

. Safety . Safety, tolerability and PK/PD Primary endpoint

. FPI Q3 2019 . FPI Q4 2017 Status . Data presented at SABCS 2019

CT Identifier NCT03332797 NCT03916744

SABCS=San Antonio Breast Cancer Symposium 65 SERD (3) (RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator

Indication Neoadjuvant ER+ BC 1L ER+ metastatic breast cancer

Phase/study Phase II Phase III

# of patients N=215 N=978

• ARM A: Single agent followed by combo with palbociclib . Arm A: SERD(3) plus palbociclib • ARM B: anastrazole followed by anastrazole plus palbociclib . Arm B: letrozole plus palbociclib Design

. Progression-free survival Oncology Primary endpoint . Safety, tolerability and PK/PD

. FPI Q3 2020 . FPI Oct 2020 Status

CT Identifier NCT04436744 NCT04546009

66 Crenezumab (RG7412) Humanized mAb targeting all forms of A

Indication Alzheimer’s Prevention Initiative (API) Colombia

Phase II Phase/study Cognition study

# of patients N=252

. ARM A: PSEN1 E280A mutation carriers receive crenezumab SC . ARM B: PSEN1 E280A mutation carriers receive placebo Design . ARM C: non-mutation carriers receive placebo

Primary endpoint . Change on Alzheimer’s Prevention Initiative (API) Composite Cognitive Test total score at 260 weeks treatment Neuroscience . FPI Q4 2013 Status . Recruitment completed Q1 2017

CT Identifier NCT01998841

In collaboration with AC Immune 67 A=amyloid-beta Gantenerumab (RG1450) Fully human mAb binding aggregated forms of A

Indication Prodromal to mild Alzheimer’s disease

Phase III Phase III Phase/study GRADUATE 1 GRADUATE 2

# of patients N=1,016 N=1,016 104-week subcutaneous treatment period: 104-week subcutaneous treatment period: . ARM A: Gantenerumab . ARM A: Gantenerumab Design . ARM B: Placebo . ARM B: Placebo

Primary endpoint . Change in CDR-SOB at 27 months . Change in CDR-SOB at 27 months Neuroscience . FPI Q2 2018 . FPI Q3 2018 . Recruitment completed Q2 2020 . Recruitment completed Q2 2020 Status

CT Identifier NCT03443973 NCT03444870

In collaboration with MorphoSys AG 68 A=amyloid-beta; CDR-SOB=Clinical Dementia Rating Scale Sum of Boxes Gantenerumab (RG1450) Fully human mAb binding aggregated forms of A

Indication Prodromal Alzheimer’s disease Mild Alzheimer’s disease

Phase II/III Phase III Phase/study SCarlet RoAD Marguerite RoAD

# of patients N=799 N=389 104-week subcutaneous treatment period: 104-week subcutaneous treatment period: . ARM A: Gantenerumab (225 mg) . ARM A: Gantenerumab Design . ARM B: Gantenerumab (105 mg) . ARM B: Placebo . ARM C: Placebo

. Change in CDR-SOB at 2 years . Change in ADAS-Cog and CDR-SOB at 2 years (co-primary) Primary endpoint . Sub-study: change in brain amyloid by PET at 2 years

. Phase I PET data: Archives of Neurology, 2012 Feb;69(2):198-207 . FPI Q1 2014 Neuroscience . Recruitment completed Q4 2013 . Recruitment stopped Q4 2015 Status . Dosing stopped due to futility Q4 2014 . FPI Q1 2016 for open label extension . FPI in open label extension study Q4 2015 . OLE data (MRI) presented at CTAD 2017, AD/PD, AAIC 2018 and AAN . OLE data presented at CTAD 2017, AD/PD and AAN 2018 and 2019 2018 and 2019

CT Identifier NCT01224106 NCT02051608

In collaboration with MorphoSys AG A=amyloid-beta; CDR-SOB=Clinical Dementia Rating Scale Sum of Boxes; PET= positron emission tomography; ADAS-cog=Alzheimer’s Disease Assessment Scale cognitive subscale; 69 AAIC=Alzheimer’s Association International Conference; CTAD=Clinical Trials on Alzheimer's Disease; AD/PD=Alzheimer’s & Parkinson’s Diseases Congress; AAN=American Academy of Neurology; MRI=Magnetic resonance imaging Tominersen (RG6042, HTT ASO ) Antisense oligonucleotide (ASO) targeting human HTT mRNA

Indication Huntington’s disease

Phase II Phase/study Phase I/IIa OLE

# of patients N=46 N=46

. Multiple ascending doses of RG6042 administered intrathecally to adult . Patients from phase I are enrolled into OLE patients with early manifest Huntington's Disease Design

Primary endpoint . Safety, tolerability, PK and PD . Longer term safety, tolerability, PK, PD. Neuroscience

. FPI Q3 2015 . FPI Q1 2018 . Data presented at CHDI 2018 and AAN 2018 . PK/PD data presented at AAN 2019 Status . PRIME designation granted 2018 . Update presented at CHDI 2020 . Published in NEJM 2019; 380:2307-2316 . Study completed, patients moved to GEN-EXTEND OLE

CT Identifier NCT02519036 NCT03342053

In collaboration with Ionis Pharmaceuticals 70 AAN=American Academy of Neurology; NEJM=New England Journal of Medicine Tominersen (RG6042, HTT ASO ) Antisense oligonucleotide (ASO) targeting human HTT mRNA

Indication Huntington’s disease

Phase III Phase III Phase/study Generation HD1 GEN-EXTEND

# of patients N=791 N=1050

. ARM A: RG6042 120mg bimonthly Open-Label Extension study in patients participating in prior Roche and . ARM B: RG6042 120mg every four months Genentech sponsored studies Design . ARM C: Placebo bimonthly • Arm A: RG6042 120mg bimonthly • Arm B: RG6042 120mg every four months

. cUHDRS globally . Long term safety, tolerability Primary endpoint . TFC USA only Neuroscience

. FPI Jan 2019 • FPI April 2019 . Q1 2019 protocol modified to allow for bi-monthly vs four-monthly dosing, Status FPI for new protocol July 2019 . Recruitment completed Q2 2020

CT Identifier NCT03761849 NCT03842969

In collaboration with Ionis Pharmaceuticals 71 cUHDRS=composite Unified Huntington's Disease Rating Scale; TFC=total function capacity Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase

Primary progressive multiple sclerosis inhibitorIndication (BTKi) Relapsing multiple sclerosis (RMS) (PPMS)

Phase III Phase III Phase III Phase/study FENtrepid FENhance 1 FENhance 2

# of patients N=946 N=734 N=734

. ARM A: Fenebrutinib twice daily oral . Arm A: Fenebrutinib twice daily oral . Arm A: Fenebrutinib twice daily oral . Arm B: Ocrelizumab 2x300 mg IV every 24 . Arm B: Teriflunomide once daily oral . Arm B: Teriflunomide once daily oral weeks Design

. Time to onset of composite 12-week . Time to onset of composite 12-week . Time to onset of composite 12-week Immunology Primary endpoint confirmed disability progression (cCDP12) confirmed disability progression (cCDP12) confirmed disability progression (cCDP12) and annualized relapse rate and annualized relapse rate

Status . FPI expected Q4 2020 . FPI expected Q4 2020 . FPI expected Q4 2020

CT Identifier NCT04544449

72 Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase inhibitorIndication (BTKi) Rheumatoid arthritis

Phase II Phase II Phase/study ANDES Open label extension

# of patients N=578 N=578 Randomized, double-blind, parallel group study in rheumatoid arthritis Patients enter the study after completing 12 weeks of treatment in the patients: ANDES Randomized study: . Cohort 1: Fenebrutinib vs adalimumab in patients with inadequate . 200mg BID of fenebrutinib for 52 weeks Design response to previous MTX . Cohort 2: Fenebrutinib vs placebo in patients with inadequate response to previous TNF

Primary endpoint . ACR 50 at week12 and safety . ACR 50 at week12 and safety Immunology

. FPI Q3 2016 . FPI Q4 2016 Status . Recruitment completed Q1 2018; . Recruitment completed Q2 2018 . Data presented at EULAR and ACR in 2019

CT Identifier NCT02833350 NCT02983227

MTX=methotrexate; EULAR=European League Against Rheumatism; ACR=American College of Rheumatology 73 Etrolizumab (RG7413) Humanized mAb against beta 7 integrin

Indication Ulcerative colitis patients who are TNF-naïve

Phase III Phase III Phase III Phase/study HIBISCUS I HIBISCUS II GARDENIA Induction study Induction study Sustained remission study # of patients N=358 N=358 N=390

. ARM A: Etrolizumab 105mg SC q4w plus . ARM A: Etrolizumab 105mg SC q4w plus Time on treatment 54 weeks: adalimumab placebo SC adalimumab placebo SC . ARM A: Etrolizumab 105mg SC q4w plus . ARM B: Etrolizumab placebo SC plus . ARM B: Etrolizumab placebo SC plus placebo IV Design adalimumab SC adalimumab SC . ARM B: Placebo SC q4w plus infliximab IV . ARM C: Etrolizumab placebo SC plus . ARM C: Etrolizumab placebo SC plus

adalimumab placebo SC adalimumab placebo SC Immunology . Induction of remission compared with placebo . Induction of remission compared with placebo . Proportion of patients in sustained clinical Primary endpoint as determined by the Mayo Clinic Score (MCS) as determined by the Mayo Clinic Score (MCS) remission as determined by Mayo Clinic Score at week 10 at week 10 (MCS) at weeks 10, 30 and 54

. FPI Q4 2014 . FPI Q4 2014 . FPI Q4 2014 . Recruitment completed Q4 2019 . Recruitment completed Q4 2019 . Recruitment completed Q2 2019 Status . Primary endpoint met Q3 2020 . Primary endpoint not met Q3 2020 . Primary endpoint not met Q3 2020 . Data presented at UEGW 2020 . Data presented at UEGW 2020 . Data presented at UEGW 2020

CT Identifier NCT02163759 NCT02171429 NCT02136069

74 UEGW=United European Gastroenterology Week Etrolizumab (RG7413) Humanized mAb against beta 7 integrin Ulcerative colitis patients who are TNF-naïve and refractory or intolerant Ulcerative colitis patients who are refractory or Moderate to severe ulcerative colitis Indication to immunosuppressant and/or intolerant of TNF inhibitors patients corticosteroid treatment Phase III Phase III Phase III Phase/study LAUREL HICKORY COTTONWOOD Maintenance study Induction and maintenance study Open label extension study # of patients N=359 N=609 N=2,100

Induction phase: Cohort 1 (open-label): . Patients who were previously enrolled in . ARM A: Open label etrolizumab 105mg SC . ARM A: Etrolizumab induction + placebo maintenance etrolizumab phase II and phase III q4w . ARM B: Etrolizumab induction + maintenance studies and meet recruitment criteria will Design Maintenance study: Cohort 2 (blinded): receive etrolizumab 105 SC q4w . ARM B: Etrolizumab 105mg SC q4w . ARM A: Etrolizumab induction + maintenance

. ARM C: Placebo . ARM B: Placebo induction + maintenance Immunology . Maintenance of remission (at week 62) . Clinical Remission (Mayo Clinic Score, MCS) at Week 14 . Long-term efficacy as determined by Primary endpoint among randomized patients in remission at . Remission maintenance (by MCS, at Week 66) among partial Mayo Clinic Score (pMCS), Week 10 as determined by MCS patients with remission at Week 14 incidence of adverse events

. FPI Q3 2014 . FPI Q2 2014 . FPI Q3 2014 . Recruitment completed Q1 2019 . Open label induction and endoscopy data presented at . Primary endpoint not met Q3 2020 UEGW 2017 Status . Data presented at UEGW 2020 . Recruitment completed Q1 2019 . Primary endpoint met for induction, not met for maintenance Q3 2020 . Data presented at UEGW 2020 CT Identifier NCT02165215 NCT02100696 NCT02118584 75 MCS=Mayo Clinic Score; ECCO=European Crohn’s and Colitis Organisation; UEGW=United European Gastroenterology Week Etrolizumab (RG7413) Humanized mAb against beta 7 integrin

Indication Moderately to severely active Crohn’s disease Moderately to severely active Crohn’s disease

Phase III Phase III Phase/study BERGAMOT JUNIPER Induction and maintenance study Open label extension study for BERGAMOT # of patients N=1,150 N=900

. ARM A: Etrolizumab SC 210 mg (induction only) . Etrolizumab SC 105mg q4w . ARM B: Etrolizumab SC 105 mg and maintenance . ARM C: Placebo

Design Immunology Primary endpoint . Induction and maintenance of clinical remission . Safety

. FPI Q1 2015 . FPI Q2 2015 Status . Cohort 1 data presented at UEGW 2017

CT Identifier NCT02394028 NCT02403323

UEGW=United European Gastroenterology Week 76 Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5

Indication Paroxysmal nocturnal hemoglobinuria (PNH)

Phase I/II Phase/study COMPOSER

# of patients N=59 Healthy volunteers and treatment naïve and pretreated patients with PNH: . Part 1: single ascending dose study in healthy subjects . Part 2: intra-patient single ascending dose study in PNH patients Design . Part 3: Multiple-dose study in PNH patients . Part 4: Dose confirmation in PNH patients

Primary endpoint . Safety, PK, PD Immunology

. Part 1: FPI Q4 2016 . Part 2/3: FPI Q2 2017 Status . Part 4: FPI Q2 2019 . Nonclinical data published in Scientific Reports 2017 Apr; 7(1):1080 . Data presented for Part 2 and 3 at ASH 2018 and 2019

CT Identifier NCT03157635

In collaboration with Chugai 77 ASH=American Society of Hematology Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5

Paroxysmal Nocturnal Hemoglobinuria (PNH) patients switching Paroxysmal Nocturnal Hemoglobinuria (PNH) Indication from a C5 inhibitor C5 inhibitor naive patients

Phase III Phase III Phase/study COMMODORE 1 COMMODORE 2

# of patients N=250 N=200

. Arm A: Crovalimab . Arm A: Crovalimab . Arm B: Eculizumab . Arm B: Eculizumab . Arm C: Patients switching to crovalimab from ravulizumab, higher than Design labelled doses of eculizumab & C5 SNP patients (descriptive-arm)

. Non-inferiority of crovalimab compared to eculizumab - mean % change . Non-inferiority of crovalimab compared to eculizumab: Immunology in LDH level (measure of haemolysis) from baseline to week 25 - % pts with transfusion avoidance from baseline through week 25 Primary endpoint - % pts with haemolysis control, as measured by LDH <=1.5ULN from week 5-25

. FPI Q3 2020 . FPI Oct 2020 Status

CT Identifier NCT04432584 NCT04434092

In collaboration with Chugai 78 LDH=Lactate Dehydrogenase rhPTX-2 (RG6354) Recombinant human innate immunity protein pentraxin-2

Indication Idiopathic pulmonary fibrosis (IPF) Myelofibrosis

Phase/study Phase II Phase II

# of patients N=117 N=98 • Randomized, double-blind, placebo-controlled trial: 4-week screening • Multiple dose study of RG6354 period, 24-week randomized treatment period, 4-week follow-up visit (week 28) Design • RG6354 at days 1, 3 and 5 then every 4 weeks vs placebo

• Least-squares mean change in forced vital capacity (FVC) percentage of • Bone marrow response rate Immunology Primary endpoint predicted value from baseline to week 28

• Study met primary endpoint . Ongoing Status • Data published in JAMA 2018;319(22):2299-2307

CT Identifier NCT02550873 NCT01981850

JAMA=Journal of the American Medical Association 79 Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A

Center-involving diabetic macular edema Indication Neovascular age related macular degeneration (nAMD) (CI-DME)

Phase II Phase II Phase II Phase/study AVENUE STAIRWAY BOULEVARD

# of patients N=271 N=75 N=210

. ARM A: SoC (Lucentis), q4w . ARM A: SoC (Lucentis), q4w . ARM A: SoC (Lucentis), 0.3 mg q4w . ARM B: 1.5 mg faricimab, q4w . ARM B: 6mg faricimab, q>8w (short interval . ARM B: 1.5mg faricimab, q4w . ARM C: 6mg faricimab, q4w duration) . ARM C: 6mg faricimab, q4w Design . ARM D: 6mg faricimab, q4w / q8w . ARM C: 6mg faricimab, q>8w (long interval . ARM E: SoC q4w x 3 doses, switch group to 6 duration) mg faricimab q4w

. Change from baseline BCVA after 32 weeks . Change from baseline BCVA at Week 40 . Mean change from baseline BCVA at week 24 Ophthalmology Primary endpoint

. FPI Q3 2015 . FPI Q1 2017 . FPI Q2 2016 . Recruitment completed Q1 2017 . Recruitment completed Q1 2017 . Recruitment completed Q1 2017 . Data presented at Retina Society 2018 . Data presented at Retina Society 2018 (24 . Data presented at Angiogenesis 2018 and Status . Data published JAMA Ophthalmol 2020; week data) and AAO 2018 (full data) Retina Society 2018 138(9):955-963 . Data published JAMA Ophthalmol 2020; . Data published in Ophthalmology 2019 138(9):964-972 Aug;126(8):1155-1170

CT Identifier NCT02484690 NCT03038880 NCT02699450

BCVA=best corrected visual acuity; SoC=standard of care; AAO=American Academy of Ophthalmology 80 Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A

Indication Center-involving diabetic macular edema (CI-DME)

Phase III Phase III Phase/study YOSEMITE RHINE

# of patients N=900 N=900

. ARM A: Faricimab q8w . ARM A: Faricimab q8w . ARM B: Faricimab (RG7716) q8w/PTI . ARM B: Faricimab (RG7716) q8w/PTI . ARM C: Aflibercept, q8w . ARM C: Aflibercept, q8w Design

Primary endpoint . Change from baseline in BCVA at 1 year . Change from baseline in BCVA at 1 year Ophthalmology . FPI Q3 2018 . FPI Oct 2018 Status . Recruitment completed Q3 2019 . Recruitment completed Q3 2019

CT Identifier NCT03622580 NCT03622593

PTI=Personalized Treatment Interval; BCVA=best corrected visual acuity 81 Faricimab (RG7716) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A

Indication Neovascular age related macular degeneration (nAMD)

Phase III Phase III Phase/study TENAYA LUCERNE

# of patients N=640 N=640

. ARM A: Faricimab 6.0mg Q16 flex after 4 initiating doses (IDs) . ARM A: Faricimab 6.0mg Q16 flex after 4 initiating doses (IDs) . ARM B: Aflibercept 2.0mg Q8 after 3 IDs . ARM B: Aflibercept 2.0mg Q8 after 3 IDs Design

. Change from baseline in BCVA Week 40, 44 & 48 . Change from baseline in BCVA Week 40, 44 & 48

Primary endpoint Ophthalmology

. FPI Q1 2019 . FPI Q1 2019 Status . Recruitment completed Q4 2019 . Recruitment completed Q4 2019

CT Identifier NCT03823287 NCT03823300

BCVA=best corrected visual acuity 82 Port Delivery System with ranibizumab First eye implant to achieve sustained delivery of a biologic medicine

Indication wAMD

Phase III Phase II+III extension Phase/study Archway Portal

# of patients N=418 N=500

. ARM A: PDS with ranibizumab every 24 weeks . Patients from LADDER or Archway will receive refills of 100 mg/mL . ARM B: Intravitreal ranibizumab every 4 weeks ranibizumab q24w (patients without the PDS will receive the PDS and Design subsequent refills)

Primary endpoint . Change in BCVA from baseline at the average of week 36 and week 40 . Safety and long term efficacy Ophthalmology . FPI Q3 2018 . FPI Q3 2018 . Recruitment completed Q2 2019 Status . Study met primary endpoint Q2 2020 . Data presented at ASRS 2020

CT Identifier NCT03677934 NCT03683251

BCVA=best corrected visual acuity; wAMD=wet age-related macular degeneration; ASRS=American Society of Retinal Specialists 83 Port Delivery System with ranibizumab First eye implant to achieve sustained delivery of a biologic medicine

Diabetic retinopathy without Indication DME center-involved diabetic macular edema

Phase III Phase III Phase/study Pagoda Pavilion

# of patients N=545 N=160

. ARM A: PDS with ranibizumab every 24 weeks . Arm A: Intravitreal ranibizumab (X2) followed by PDS implant (refill . ARM B: Intravitreal ranibizumab every 4 weeks every 36 weeks) Design . Arm B: Q4W comprehensive clinical monitoring until participants receive PDS (refill every 36 weeks)

. Change in BCVA from baseline at the average of week 48 and week 52 . Percentage of participants with a ≥2-step improvement from baseline on Primary endpoint

the ETDRS-DRSS at Week 52 Ophthalmology

Status . FPI Q3 2019 . FPI Q3 2020

CT Identifier NCT04108156 NCT04503551

DME=diabetic macular edema; BCVA=best corrected visual acuity; ETDRS=Early Treatment Diabetic Retinopathy Study; DRSS=Diabetic Retinopathy Severity Scale 84 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Spark

85 pRED oncology development programs

Molecule Indication Phase # of patients Status CT Identifier Oncology I 60 FPI Q4 2015; Part B/C FPI Q3 2017 NCT02627274 Solid tumors simlukafusp alfa Ib 360 FPI Q1 2018 NCT03386721 (FAP-IL2v FP, RG7461) 1L Renal cell carcinoma Ib 110 FPI Q1 2017 NCT03063762 1L/2L+ melanoma I 150 FPI Q2 2019 NCT03875079 FPI Q2 2018 FAP-4-1BBL (RG7827) Solid tumors I 200 Data presented at ESMO 2020 R/R B cell non-Hodgkin’s CD19-4-1BBL (RG6076) I 207 Part I: FPI Q3 2019; Part II: FPI Q3 2020 NCT04077723 lymphoma PD1-IL2v (RG6279) Solid tumors I 440 FPI Q2 2020 NCT04303858 FPI Q4 2014 Ia 149 NCT02324257 Data presented at ASCO 2017 cibisatamab CEA-positive solid tumors FPI Q1 2016 (CEA x CD3, RG7802) Ib 228 NCT02650713 Data presented at ASCO 2017 3L+ MSS mCRC Ib 46 FPI Q1 2019 NCT03866239 PD1-TIM3 (RG7769) Solid tumors Ia/b 280 FPI Q4 2018 NCT03708328 PD1-LAG3 (RG6139) Solid tumors I 320 FPI Q4 2019 NCT04140500 FPI Q1 2016; Part II FPI Q2 2018 selicrelumab (RG7876) Solid tumors Ib 170 Selicrelumab+vanucizumab arm no NCT02665416 longer recruiting Anti-CD25 (RG6292) Solid tumors I 110 FPI Q4 2019 NCT04158583 86 TLR7 agonist (4) (RG6115) Hepatocellular carcinoma I 100 FPI July 2020 NCT04338685 pRED neuroscience development programs

Molecule Indication Phase # of patients Status CT Identifier Neuroscience Brain Shuttle gantenerumab (RG6102) Alzheimer's disease I ~60 FPI Q3 2019 NCT04023994 II 36 FPI Q4 2018; LPI Q3 2019 ralmitaront Schizophrenia II 345 FPI Q4 2019 NCT03669640 (partial TAAR1 agonist, RG7906) II 308 FPI Q3 2020 Study did not meet its primary objective, but showed signals of efficacy on core prasinezumab1 NCT03100149 Parkinson’s disease II 316 motor signs in PD. Key study data (anti-αSynuclein, RG7935, PRX002) (PASADENA) presented at MDS Sep 2020. The 52-week blinded extension (Part 2) is ongoing I 105 FPI Q4 2017 GABA-Aa5 PAM (RG7816) Autism I 15 FPI Q2 2018 NCT03507569 Neurodevelopmental NME (RG7637) I 80 FPI July 2020 NCT04475848 disorders UBE3A LNA Angelman syndrome I 66 FPI Q3 2020 NCT04428281

87 Partner: 1Prothena pRED infectious diseases, immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Infectious Diseases FPI Q4 2016 TLR7 agonist (3) (RG7854) Chronic hepatitis B I 150 NCT02956850 Data presented at APASL 2019 FPI Q4 2016 CpAM (RG7907) Chronic hepatitis B I/II 190 Data presented at EASL 2018, 2019 & NCT02952924 2020 TLR7 agonist (3) + CpAM NCT04225715 Chronic hepatitis B II 65 FPI July 2020 (RG7854 + RG7907) (PIRANGA) NME (RG6084) Chronic hepatitis B I 27 FPI Q1 2019

Immunology IgG-IL2 FP (RG7835) Ulcerative Colitis Ib 50 FPI Q2 2019 NCT03943550

Ophthalmology NME (RG6179)1 DME I 50 FPI July 2019 NCT04265261 NME (RG7774) Retinal disease II 180 FPI Q2 2020 (CANBERRA)

88 Partner: 1Sesen Bio Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Spark

89 gRED oncology development programs

Molecule Indication Phase # of patients Status CT Identifier Oncology Metastatic solid tumors with KRAS G12C (RG6330) I 108 FPI Q3 2020 NCT04449874 KRAS G12C mutation FcRH5 x CD3 (RG6160) R/R multiple myeloma I 80 FPI Q3 2017 NCT03275103 Metastatic HER2-expressing HER2 x CD3 (RG6194) I 440 FPI Q2 2018 NCT03448042 cancers BCMA x CD16a (RG6296)1 R/R multiple myeloma I 55 FPI Q3 2020 NCT04434469

Locally advanced or NME (RG6286) I 67 FPI Q3 2020 NCT04468607 metastatic colorectal cancer

IL15/IL15Ra-Fc (RG6323)2 Solid tumors I/II 250 FPI Q1 2020 NCT04250155 FPI Q4 2017 Solid tumors Ia/IIb 770 NCT03289962 Individualized Neoantigen-Specific Data presented at AACR 2020 3 Therapy (iNeST) (RG6180) NCT03815058 1L advanced melanoma II 132 FPI Q1 2019 (IMcode001)

90 Partner: 1Affimed, 2Xencor, 3BioNTech gRED immunology development programs

Molecule Indication Phase # of patients Status CT Identifier Immunology Inflammatory diseases Ib 90 FPI Q2 2016 NCT02749630 IL-22Fc (RG7880) Inflammatory bowel disease II 270 FPI Q4 2018 NCT03558152 NME (RG6287, GDC-8264) Inflammatory bowel disease I 114 FPI Jan 2020 FPI Q4 2017 ACTRN1261700 NME (RG6151, GDC-0214) Asthma I 84 Recruitment completed Q1 2018 1227381p ACTRN1261900 NME (RG6244, GDC-4379) Asthma I 84 FPI Q2 2019 0227190p

Anti-tryptase Asthma I 70 FPI Q1 2018 (RG6173, MTPS9579A) Asthma IIa 160 FPI Q4 2019 NCT04092582

ST2 MAb FPI Q3 2016 NCT02918019 Asthma IIb 515 (RG6149, AMG 282, MSTT1041A)1 Recruitment completed Apr 2018 (ZENYATTA)

ST2 MAb (RG6149, AMG 282, Adult hospitalised with severe NCT04386616 II 390 FPI Q2 2020 MSTT1041A) or IL-22Fc (RG7880)2 COVID-19 pneumonia (COVASTIL)

NME (RG6315, MTBT1466A) Systemic Sclerosis I ~24 FPI Q3 2020

91 Partner: 1Amgen, 2Amgen for ST2 MAb gRED neuroscience, ophthalmology and metabolic diseases development programs

Molecule Indication Phase # of patients Status CT Identifier Neuroscience FPI Q4 2017 Prodromal to mild NCT03289143 II 457 Primary endpoint not met Q3 2020 Alzheimer’s disease (TAURIEL) Semorinemab (RG6100)1 Data at CTAD 2020 NCT03828747 Moderate Alzheimer’s disease II 260 FPI Q1 2019 (LAURIET)

Ophthalmology NCT03972709 NME (RG6147) Geographic atrophy II 285 FPI Q2 2019 (GALLEGO)

Metabolic Diseases FPI Q4 2015 Metabolic diseases Ia 79 NCT02593331 Recruitment completed Q1 2017 FGFR1 X KLB (RG7992) FPI Q1 2017 Metabolic diseases Ib 140 NCT03060538 Recruitment completed Q2 2019 NASH II 260 FPI Q3 2020 NCT04171765

92 Partner: 1AC Immune, 2Seagen Inc., Symphogen Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)

Spark

93 Hemophilia A Unique gene therapy platform

SPK-8011 SPK-8016 Molecule (RG6357) (RG6358)

Indication Hemophilia A Hemophilia A with inhibitors to Factor VIII

Phase/study Phase I Phase I/II Phase I/II

# of patients N=100 N=30 N=30

. Long term follow up study of patients who . Gene transfer, dose-finding safety, tolerability, . Gene transfer, dose-finding safety, tolerability, and have received SPK-8011 in any prior and efficacy study of SPK-8011 efficacy study of SPK-8016 in individuals with FVIII

Design Spark-sponsored SPK-8011 study inhibitors Hemophilia

. Safety . Safety and changes from baseline in FVIII . Safety; peak and steady state FVIII activity levels at Primary endpoint activity levels at week 52 week 52 . Updated data presented at ISTH 2020

Status . Ongoing . Ongoing . Ongoing

CT Identifier NCT03432520 NCT03003533 NCT03734588

94 Choroideremia Unique gene therapy platform

SPK-7001 Molecule (RG6367)

Indication Choroideremia

Phase/study Phase I/II

# of patients N=15

. Safety study in subjects with CHM (choroideremia) gene mutations

Design

. Safety and tolerability Primary endpoint Ophthalmology

. FPI Q1 2015 Status . Recruitment completed Q2 2017 CT Identifier NCT02341807

95 Doing now what patients need next